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Human immununodeficiency virus (HIV) infection is the leading cause of death due to viral 
infections worldwide.  In the absence of an effective vaccine or consistent male condom use, 
there is a clear need for female-controlled preventatives such as topical vaginal microbicides.  
Recent attention has been focused on developing natural antimicrobial peptides, as anti-retroviral 
microbicides.   Increasing evidence suggests that cationic antimicrobial peptides such as 
defensins are effective HIV-1 inhibitors.  Human alpha- and beta-defensins contribute 
substantially to innate immune defenses against microbial and viral infections.  Certain 
nonhuman primates also produce theta-defensins – 18 residue cyclic peptides that are potent 
HIV-1 entry inhibitors.  Multiple human theta-defensin genes exist, but they harbor a premature 
termination codon that blocks translation.  Consequently, the theta-defensins (retrocyclins) 
encoded within the human genome are not expressed as peptides.  In vivo production of theta-
defensins in rhesus macaques involves the post-translational ligation of two nonapeptides, each 
derived from a 12-residue “demidefensin” precursor.  Neither the mechanism of this unique 
process nor its existence in human cells is known.  To ascertain if human cells retained the 
ability to process demidefensins, we transfected human promyelocytic cells with plasmids 
containing repaired retrocyclin-like genes.  The expected peptides were isolated, their sequences 
were verified by mass spectrometric analyses, and their anti-HIV-1 activity was confirmed in 
vitro.  Our study reveals for the first time, to our knowledge, that human cells have the ability to 
make cyclic theta-defensins.  Given this evidence that human cells could make theta-defensins, 
we attempted to restore endogenous expression of retrocyclin peptides.  Since human theta-
defensin genes are transcribed, we used aminoglycosides to read-through the premature 
termination codon found in the mRNA transcripts.  This treatment induced the production of 
 iii 
intact, bioactive retrocyclin-1 peptide by human epithelial cells and cervicovaginal tissues.  The 
ability to reawaken retrocyclins genes from their 7 million years of slumber using 
aminoglycosides could provide a novel way to secure enhanced resistance to HIV-1 infection.   
 
Our studies on retrocyclin reveal that they are potential candidates to develop as topical vaginal 
microbicides to prevent sexual transmission of HIV-1.  Mucosal surfaces of the vagina are the 
portals for heterosexual transmission of HIV-1 and therefore play a fundamental role in the 
pathogenesis of primary infection.  In a search for direct biological evidence for the role of 
human vaginal fluid in innate host defense, we characterized the anti-HIV-1 function of cationic 
polypeptides within minimally manipulated vaginal fluid.  In our studies, we revealed that 
vaginal fluid confers intrinsic anti-HIV-1 properties against both X4 and R5 strains of HIV-1, 
and could protect against HIV-1 infection and reduce proviral genome integration in organotypic 
cultures of human cervicovaginal tissue.  The majority of this activity was contained in the 
cationic polypeptide fraction, and the depletion of cationic polypeptides using a selective cation-
exchange resin ablated most of the intrinsic activity against HIV-1.  By adding the cationic 
polypeptide fraction to depleted vaginal fluid, we were able to restore activity against HIV-1.  
Using a proteomic approach, we identified 18 cationic polypeptides within vaginal fluid, nearly 
all of which are either known antimicrobials or have other purported roles in host defense.  
Interestingly, physiologic concentrations of 13 of the cationic polypeptides were alone not active 
against HIV-1, yet in concert they partially restored the anti-HIV-1 activity of cation-depleted 
vaginal fluid.  These results suggest that synergism between cationic polypeptides is complex 
and full anti-HIV-1 activity likely involves the aggregate of the cationic peptides and proteins in 
the acidic human vaginal fluid.  Interestingly, retrocyclins retained complete anti-HIV-1 activity 
 iv 
in the presence of human vaginal fluid.  Therefore expression of retrocyclin peptides can help 
activate the natural defense mechanism against HIV-1. 
 
We next investigated the regulation of expression of retrocyclin (pseudo)gene.  We identified a 
putative interferon response cluster upstream of the retrocyclin gene.  The activity of this cluster 
was upregulated when treated with IFN-  although to a modest extent.  Interestingly, the cluster 
also contained the binding site for an Interferon Consensus Sequence Binding Protein (ICSBP), a 
known repressor of the IFN inducible genes.  Deletion of the ICSBP site or addition of a known 
inhibitor of ICSBP resulted in the increase in the activity of the cluster, indicating a role for 
ICSBP in the negative regulation of expression of retrocyclins.  Collectively our data suggest 
that the expression of this ancestral gene is tightly regulated in both a positive and negative 
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CHAPTER ONE: GENERAL REVIEW 
 
1.1 Need for topical microbicides against HIV-1 
  The World Health Organization estimates that 15.5 million women were infected with HIV by the 
end of 2007, which represents about 50% of total people with HIV worldwide [1,2].  Heterosexual 
intercourse continues to be the predominant mode of transmission of this pandemic and women are 
more susceptible to HIV-1 infection than men [3-5].  Although the current HIV treatments reduce 
mortality and morbidity, access to these medications are not available in many developing and 
underdeveloped countries.  In the absence of effective treatments or vaccines for HIV, many of the 
current efforts are aimed at developing new measures to prevent transmission of HIV.  Condoms 
are an effective preventive measure but their use is often not negotiable by women due to socio-
economic and cultural reasons.  Effective female-controlled prophylactic measures that can protect 
against HIV-1 infection are needed.  Topical microbicides, which can be used by the receptive 
partner, represent a new avenue for the prevention of sexual transmission of HIV.   
 
1.2 Update on candidate microbicides  
Much attention and effort has been given to developing detergents (benzalkonium chloride or 
octoxynol-9 or sodium lauryl sulfate or nonoxynol-9/N-9) that function as a spermicide as well as 
a microbicide [6-8].  The most promising amongst them nonoxynol-9/N-9, however, failed the 
clinical trials due to its detrimental effect on human epithelium [9-15]. Currently, there are about 
29 diverse candidate microbicides in development which can be broadly categorized as i) agents 
that disrupt the viral envelope, ii) agents that inhibit entry or fusion of the virus, and iii) agents that 





Several natural and synthetic polymers that can directly or indirectly disrupt the viral envelope are 
currently being tested.  These include anionic polymers or surfactants that contain sulfated esters 
of polysaccharides (Example: dextran sulfate/Emmelle™ [16-18], cellulose sulfate/Ushercell™ 
[19,20], Carrageenan/ Carraguard™ [21-28]) or sulfonated benzene or naphthalene (Polystyrene 
sulfonate, Polynaphtalene sulfonate/PRO2000 [29-36]) or polycarboxylates (Carbomer974P 
/BufferGel™ [37-41]) and cellulose acetate phthalates [42,43].  However, some of the 
disadvantages of using anionic polymers as topical microbicides are that they are not broad-
spectrum in their activity, they induce proinflammatory cytokines, they have a high toxicity index, 
they disturb the natural microflora, and they induce ulceration of the vaginal epithelium [44-48].  
Natural plant extracts such as Praneem™ that exhibit anti-retroviral activity are under preclinical 
development.  Although Phase-II efficacy trials of this herbal extract have been promising so far, 
the toxicological and long term effects of the repeated use of these formulations on reproductive 
health has yet to be evaluated [49-52].    
 
The second category of anti-HIV-1 microbicides that are currently in the pipeline undergoing 
preclinical investigations include viral fusion inhibitors which block the viral proteins or host 
receptors (CD4, CCR5 or CXCR4) utilized by the virus for entry.  Peptidic ligands for receptors 
CD4 (PRO 542) [53,54] or CCR5 (Maraviroc [55-59], PRO-140 [60-62], PSC-RANTES [63-65]) 
or CXCR4 (T22, T134, ALX40-4C, CGP 64222) [66,67] show promising anti-HIV-1 activity.  An 
important factor to be considered here is that these chemokine receptors have other functions in the 
body, which if blocked may lead to undesirable side effects.  Therefore, fusion inhibitors that 




the host.  Many fusion inhibitors (cyanobacterial lectin Cyanovirin-N [68-73], Enfuvirtide (T20) 
and its derivatives [74-81]) that block gp41 and prevent entry of the virus to the host membrane 
have undergone clinical testing.   
  
A more recent ‘probiotic’ method that acts as fortifiers of vaginal host defense is the use of 
capsules of Lactobacilli, the most common vaginal bacteria.  Certain strains of Lactobacilli sp. 
release lactic acid and hydrogen peroxide which can inactivate HIV-1.  Epidemiological studies 
have shown a correlation between increased colonization of lactobacillus and decreased HIV-1 
transmission.  Bio-engineered Lactobacilli that can express microbicides that target HIV-1 and 
serve as mucosal drug delivery systems are currently being explored [82-86].  The development of 
an effective microbicide against HIV-1 also depends on our emerging knowledge of the sexual 
transmission of the virus.   
 
1.3 Transmission of HIV from the mucosal surface to target cells   
Sexual transmission of HIV is predominantly through the mucosal surfaces, particularly the 
vaginal and rectal mucosa [4].  Underlying the vaginal and rectal mucosa there are dendritic cells, 
macrophages and T-cells that express CD4 receptor, a primary HIV-1 receptor. Apart from the 
CD4 receptor, the virus also utilizes secondary chemokine co-receptors CCR5 and CXCR4 to gain 
entry into target cells.  The target cells express more of the CCR5 receptor than CXCR4 receptor 
on the cell surface.  Consequently, R5 (M-tropic) strains of HIV-1, which utilize CCR5 as a co-
receptor for entry, are the predominantly sexually transmitted strains [87-98].  Co-receptor usage 
plays a critical role in HIV-1 disease progression and HIV-1 transmitted in vivo is generally M-




CXCR4 as a co-receptor (Reviewed in [99]).  There are several strains of HIV due to the error 
prone nature of reverse transcriptase.  Based on the genetic similarities of these strains they are 
classified into 3 major groups: Major group (M), Outlier group (O) and New group (N) (Reviewed 
in [100]).  More than 90% of HIV-1 infections belong to HIV-1 group M, while Group O appears 
to be restricted to west-central Africa and group N, isolated in 1998 in Cameroon, is extremely 
rare.  Within group M there are atleast 9 different genetically distinct subtypes or clades of HIV-1 
(subtypes A, B, C, D, F, G, H, J and K) [100-102].  Subtype B has been the most common subtype 
that has been isolated from many parts of the world [101].  An individual can be infected with 
more than one subtype of HIV-1 and occasionally, the two viruses of different subtypes can 
hybridize to create a more virulent recombinant virus [102-104].  Moreover, it has been observed 
that certain HIV-1 subtypes are predominantly associated with a specific mode of transmission.  In 
particular, subtype B is spread mostly by homosexual contact and intravenous drug use (essentially 
via blood), while subtype C was associated with heterosexual epidemics (via a mucosal route) 
[105].  Whether there are biological causes for the observed differences in transmission routes 
remains a subject of debate.  
 
 The mechanism by which the virus shuttles across the mucosal epithelium and infects the 
underlying target cells is not clear.  One of the proposed mechanisms involves M cells, specialized 
cells present in the gastrointestinal and rectal epithelium that aid in delivering the virus across the 
tight epithelial layer.  The dendritic cells (DCs) can directly bind the HIV-1 envelope protein 
gp120 via a C-type lectin DC-SIGN and shuttle the virus across the epithelial layer in order to 





The fusion of HIV into target cells involves the binding of the host CD4 receptor and appropriate 
secondary receptor to the viral envelope glycoproteins gp120 and gp41 subunits.  The mechanism 
of viral fusion involves two helical regions of gp41, an N-terminal heptad repeat (HR1) and a C-
terminal heptad repeat (HR2) [108-110].  The HR1 and HR2 helical regions form a six-helix-
bundle, in which three -helices formed by HR2 peptides pack in an antiparallel manner against a 
central HR1 homotrimer.  This six-helix bundle aids and stabilizes the formation of a pore on the 
host cell membrane, which allows the transfer of viral genome and proteins into the host cells 
[109,110].  Despite a wealth of knowledge on HIV propagation / infection of immune cells, early 
events from the breach of vaginal mucosa to the establishment of infection are poorly understood 
[4].  Moreover, the vaginal mucosa is a complex environment consisting of numerous endogenous 
antimicrobial components that contribute to innate host defense.  
 
1.4 Endogenous antimicrobial components of vaginal mucosa  
Cationic antimicrobial proteins are integral components of the vaginal mucosa that contribute to 
the innate antiviral activity.  Many antimicrobial peptides including lysozyme, lactoferrin, 
calprotectin, secretory leukocyte protease inhibitor (SLPI), human neutrophil peptides (HNP-1, -2 
& -3) !"#$ %-defensins [111,112], are released into the vaginal fluid by the epithelial cells and 
neutrophils, and likely contribute to the innate defense of this surface.   
 
Although reported evidence is available for the activity of vaginal fluid against pathogens, 
attention to its role in protecting against HIV-1 virus has been given only recently. Several studies 
have analyzed the antiviral properties of the three most abundant proteins on mucosal surfaces: 




absorption and penetration of HIV-1 virus in vitro [113,114] although the activity was only 
modest.  Recent data suggests that SLPI, secreted by the mucosal epithelial and acinar cells, blocks 
HIV-1 infection of monocytes and T cells by preventing internalization of the virus [114-117].  
Several reports have shown that the level of SLPI is reduced in vaginal fluid of HIV-infected 
persons.  However, other reports suggest that SLPI has no effect on HIV replication [118], and this 
debate persists.   
 
Other known effectors of natural host defense present in vaginal mucosal secretions are defensins, 
a large family of cationic antimicrobial peptides.  Defensins are the most widely studied family of 
antimicrobial peptides.  They contain six cysteines that form three disulphide- bridges and are 
predominantly composed of %-sheets.  Based on the position of the cysteines and the 
intramolecular disulphide bonds, defensins are grouped in to three subfamilies: &-defensins, %-
defensins and '-defensins [119-127].  Alpha-defensins (HNP-1 to -3) inhibit HIV-1 replication in 
vitro by two mechanisms: in the absence of serum, they inhibit HIV-1 replication before viral 
integration in CD4+ T cells, and in the presence of serum, they interfere with the signaling 
pathways on target cells and block the nuclear import and transcription of the HIV-1 genome [128-
130].  Human -defensins have been shown to inhibit HIV-1 replication by modulating the 
CXCR4 co-receptor and also by interacting directly with the HIV-1 virions [131].  It is to be noted 
that many of the above mentioned studies analyzed the effect of only one or two antimicrobial 
peptides, and thus the synergistic activity of these peptides in a biologically relevant system was 
not explored.  Using an integrated proteomic approach we identified the cationic antimicrobial 
peptides of vaginal fluid.  Further we demonstrated that these peptides contribute to the innate anti-




Despite the presence of these numerous antiviral peptides, HIV-1 transmission is on the rise.  In 
our efforts to develop effective therapeutics against this virus, we have focused our attention on the 
third subclass of defensins, known as theta-defensins.  Synthetic human theta-defensins 
(retrocyclins) were found to be potent inhibitors of HIV-1 entry [120,128,133-135], and are the 
subject of Chapter 2.  
 
1.5 Retrocyclins: a potent anti-retroviral peptide 
Theta-defensins are the most recently identified defensin subfamily, isolated initially from 
leukocytes and bone marrow of the rhesus monkey Macacca mulatta [136].  Theta-defensins are 
expressed in Old World monkeys and orangutans($)*+,-,.$'-defensin genes (DEFT) in humans 
are pseudogenes [134].  A premature termination codon mutation in the signal peptide region 
prevents translation of human DEFT mRNA [134].  The structure of a human DEFT pseudogene 
and predicted cDNA is shown in Figure 1.1A.  Multiple copies of the human DEFT pseudogenes, 
likely derived by gene duplication, are located in the chromosome 8p23 region which is consistent 
with the location of many &-defensin and –defensin genes [134,137,138].  Phylogenetic analysis 
.,-,!/0$1)!1$2345$6,",0$7!8$)!-,$9,,"$#,.:-,#$98$7;1!1:*"$*<$&-defensin genes (DEFA) in Old 
World monkeys and must have arisen during evolution after the orangutan and human lineages 
diverged.  Interestingly, orangutans have both the intact DEFT gene and the DEFT pseudogenes in 
their genome [134].  Sequence homology between orangutan alpha defensin (DEFA) and human 






Figure 1.1: Structure of Human DEFT-pseudogene. A) Structure of Human DEFT-1 pseudogene 
showing the relative length and position of the 3 exons (5’UTR, Exon-2 and Exon-3) and 2 introns.  The red lines 
represents termination codon, orange block represents truncated C-terminal domain of alpha-defensin and the blue 
block represents the 3’ region of the pseudogene.  B) An alignment of translated human DEFT-1 pseudogene and 
alpha-defensin coded by DEFA-1 of orangutan.  “-“represents termination codons.  The * indicates the mutated 17th 
residue with a termination codon in DEFT-1 and a glutamine (Q) in DEFA-1.  
 
The theta-defensin nascent peptides in rhesus monkeys (RTD) undergo extensive post-translational 
modification to give rise to the biologically active, mature theta-defensin peptide [136,139,140].  
Mature theta-defensins are composed of 18 residues created by the processing and subsequent 
fusion of two precursor propeptides.  Neither the exact mechanism nor the succession of events in 
this complex pathway is known. Each of the two precursor propeptides generates a nonapeptide 
containing three cysteines contributing to the three disulphide-bonds in the mature peptide.  Also, 
the two processed nonamers undergo mutual head-to-tail fusion resulting in a macrocyclic final 




nonapeptides (DEFT-1 and DEFT-4) as indicated in Figure 1.2.  If the premature termination 
codon in these genes were restored to a conserved glutamine, then there would be three possible 
retrocyclin peptides that could be expressed from the two precursor polypeptides.  These possible 
retrocyclin peptides and their putative post-translational processing are illustrated in Figure 1.2.   
 
 
Figure 1.2: Putative post-translational modification of retrocyclin peptides.  Figure shows a 




transcript encoding the signal peptide, propiece and the mature peptide region.  17Q represents the codon on rescued 
retrocyclin cDNA in which the mutant termination codon (  /red) was replaced by a conserved glutamine (Q / dark 
blue).  The putative post-translational modification process in which the precursor peptides that contain the 
nonapeptide undergo 1) an unknown enzymatic cleavage followed by 2) disulfide-bond formation and 3) cyclization 
by ligation of the N-and C-termini of the two nonapeptides.  The three possible mature retrocyclin peptides that could 
be formed from homodimers of DEFT-1 nonapeptide (RC-100), heterodimers of DEFT-1 and DEFT-4 nonapeptides 
(RC-100b), and homodimers of DEFT-4 nonapeptide (RC-100c) are indicated.  
 
Synthetic retrocyclins created by solid-state synthesis exhibited properties similar to rhesus theta-
defensins [141].  They also were shown to inhibit early stage HIV-1 infection and replication of 
both X4 and R5 viruses in cell lines (H9) and primary CD4+ lymphocytes [141,142].  Of particular 
interest was a lysine retrocyclin congener (RC-101) that was twice as active as the native RC-100 
peptide, and protected PBMCs completely against HIV-1 infection [135].  Both RC-100 and RC-
101 exhibited broad-spectrum and enhanced activity against over two dozen primary isolates from 
several clades of HIV-1 [128,143].  They are not cytotoxic to human cell lines and when applied 
topically to organotypic cervicovaginal tissues they induced minimal inflammation and tissue 
damage [144].  Retrocyclins remain active in the presence of acidic vaginal fluid and likely act in 
synergy with the other antimicrobial peptides of vaginal secretions.  Retrocyclins, due to their 
many desirable properties discussed above, are potent candidate topical microbicides that could 
protect against HIV infection.   
 
Retrocyclins prevent HIV-1 entry by inhibiting the fusion of HIV-1 envelope by selectively 
binding to the C-terminal heptad repeat region of gp41 thereby blocking 6-helix bundle formation 




retrocyclins for 100 days showed that the viral envelope gained modest resistance [147].  It is 
ironic that DEFT genes are silenced in the human genome, since retrocyclins are not only active 
against HIV-1, but also against several other viruses including Influenza A [148] and Herpes 
Simplex virus type I [149].  We envisioned that restoring the endogenous expression of 
retrocyclins in human cells could help strengthen the innate host defense against many pathogens. 
 
Despite a large body of information available on the properties of retrocyclins, certain questions 
remain unanswered.  If retrocyclin genes were still intact, can active, correctly folded retrocyclins 
be expressed in human cells?  Moreover, will endogenous production of retrocyclins confer 
protection against HIV-1 infection?  To answer these questions, we restored the premature 
termination codon using site-directed mutagenesis and found that human cells have still retained 
the machinery to process and create macrocyclic retrocyclin peptides [150].  We next explored 
alternative ways to activate the endogenous expression of retrocyclins using aminoglycosides that 
can allow read through of the premature termination codon in human cells [151-155].  Importantly, 
restoring the expression of retrocyclins in human cells and cervicovaginal tissues conferred 










CHAPTER TWO: REAWAKENING RETROCYCLINS: ANCESTRAL 
HUMAN DEFENSINS ACTIVE AGAINST HIV-1 
 
2.1 Introduction 
Nearly 33 million people are infected with HIV worldwide [156,157], and despite extensive efforts 
there are no effective vaccines or other countermeasures to protect against HIV transmission [158].  
In our attempts to find effective anti-HIV agents, our group determined that certain synthetic -
defensins called “retrocyclins” are potent inhibitors of HIV-1 infection [128,133,141,143,159].    
Retrocyclins belong to a large family of antimicrobial peptides known as defensins, all of which 
are cationic, tri-disulfide bonded peptides that have important roles in innate host defense.  Based 
on the position of the cysteines and the disulfide bonding pattern, defensins are grouped into 3 
subfamilies:  -defensins, -defensins and -defensins [121,160].  
 
-Defensins such as retrocyclin have a cyclic peptide backbone, derived from the head-to-tail-
ligation of two peptides that each contributes nine amino acids to form the 18 residue mature 
peptide [136].  -Defensins are the only known cyclic peptides in mammals and were originally 
isolated from rhesus macaque leukocytes and bone marrow [136,139,161].  While -defensin 
peptides are produced in old world monkeys and orangutans, in humans they exist only as 
expressed pseudogenes [134].  A premature termination codon in the signal peptide portion of 
human retrocyclin mRNA prevents its translation.  The retrocyclin gene is otherwise remarkably 
intact, showing 89.4% identity with rhesus -defensins.  Its genetic information was utilized to 
recreate retrocyclins synthetically and confirm their activity against both X4 and R5 strains of 




Retrocyclins inhibit the fusion of HIV-1 Env by selectively binding to the C-terminal heptad repeat 
region on gp41 blocking 6-helix bundle formation [145,146].  RC-101 is a congener of retrocyclin 
with a single arginine to lysine substitution that retains structural and functional similarity to 
retrocyclin [141].  RC-101 exhibited enhanced anti-HIV-1 activity against over two dozen primary 
isolates from several clades [128,143], and did not induce inflammation or toxicity in organotypic 
models of human cervicovaginal tissue [162].  Continuous passaging of HIV-1 BaL in the presence 
of sub-inhibitory concentrations of RC-101 for 100 days induced only minimal viral resistance 
[147].  Given these beneficial attributes, we envisioned that restoring the endogenous expression of 
retrocyclins in humans would provide an effective and natural way of combating HIV-1 infection. 
 
In the current study, we restored the translation of this evolutionarily lost retrocyclin peptide by 
ablating the premature termination codon using site-directed mutagenesis, and analyzed whether 
human cells can synthesize biologically active retrocyclins.  We found that promyelocytic HL60 
cells stably transfected with retrocyclin constructs in which the premature termination codon was 
corrected could express retrocyclins.  Application of the expressed retrocyclins to TZM-bl cells, 
PM1 cells, and PBMCs conferred protection against HIV-1 infection.  Moreover, mass 
spectrometric techniques confirmed the presence of correctly folded mature retrocyclin peptides.  
We also explored methods to read-through the premature termination codon within the retrocyclin 
pseudogene.  Previous reports revealed that aminoglycoside antibiotics could suppress the 
termination codon of pseudogenes and disease-associated nonsense mutations [151,153-155,163-
165].  In bacteria, aminoglycosides bind strongly to the decoding site on the 16S rRNA, thereby 
hindering protein synthesis [166].  However, in eukaryotes, aminoglycosides bind to the eukaryotic 




suppresses the termination codon through the incorporation of an amino acid in its place [167].  
Herein, we utilized aminoglycosides to induce translational read-through of the -defensin 
pseudogene, which restored the expression of functional anti-HIV-1 retrocyclin peptides in human 
cervicovaginal tissue models.  Topical application of aminoglycosides to produce endogenous 
retrocyclins in the vaginal mucosa might soon be an effective preventative to combat sexual 
transmission of HIV-1.   
 
2.2 Materials and Methods  
2.2.1 Maintenance of cells, tissues and viruses 
 
HL60 cells [168,169] obtained from ATCC were cultured in Iscoves’s DMEM with 20% FBS, 100 
U/ml penicillin and 100  g/ml streptomycin (I20).  TZM-bl cells [170] stably expressing CD4, 
CCR5 & CXCR4, has firefly luciferase gene under the control of HIV-1 promoter (from Dr. 
Kappes, Dr. Wu and Tranzyme Inc).  TZM-bl, HOS-CD4-CCR5 [171,172] (from Dr. Landau), 
PM1 cells [173], (from Dr. Reitz) and HIV-1 BaL, an R5 tropic strain, were all procured through 
the NIH AIDS Research and Reference Reagent program.  HIV-1 BaL viral stocks were prepared 
by infecting PM1 cells [147].  Peripheral blood mononuclear cells (PBMC) were isolated from 
blood drawn from a healthy HIV-1 seronegative donor as per the guidelines of the institutional 
review board of University of Central Florida.  PBMCs were isolated using Lymphosep® (MP 
biomedicals LLC, Solon, OH), and cultured in RPMI-1640 medium with 10% FBS (R10) 
supplemented with 50 Units of IL-2 (R10-50U) and 5  g/ml of phytohemagglutinin (PHA) for 3 
days.  The cells were then resuspended in R10-50U at a density of 0.8 x 106 cells/ml and grown for 




Cervicovaginal tissues (EpiVaginal ™) were obtained from MatTek Corp., Ashland, MA and 
maintained in proprietary growth medium as per the company’s guidelines.   The tissues were 
composed of a full-thickness, stratified vaginal-ectocervical layer intermixed with Langehans cells 
and underlying lamina propria.  The tissues were allowed to grow on transwell cell culture inserts 
at the air-liquid interface. 
 
2.2.2 Creation of retrocyclin constructs and stably transfected HL60 cells 
 
Retrocyclin cDNA was amplified from human bone marrow cDNA and cloned into pCRII-TOPO 
vector (Invitrogen, Carlsbad, CA).  Two mutations, Termination codon ( 17)! Gln (Q17) and 
Arg (R70)!Lys (K70) were introduced, either 17Q alone (RC-100) or both (RC-101) using 
Quick change® site-directed mutagenesis (Stratagene, LaJolla, CA) and subcloned in-frame into 
the phCMV-luc-FSR vector (Genlantis, San Diego, CA) to generate four constructs R1, R3, A1 
and A3 (Figure 2.1A).  Plasmids R1 and A1 encode RC-100 nonapeptide while R3 and A3 encode 
RC-101 nonapeptide.  Constructs A1 and A3 have a longer insert that includes additional 
downstream residues.  HL60 cells (107 cells/ 400 l Iscove’s DMEM) were co-transfected with 2 
 g each of linearized R1, R3 or A1, A3 or phCMV-luc vector alone, by electroporation 
(exponential decay wave mode- 280 V; 975  F) and selected in I20 medium with 300  g/ml G418 
sulfate.  Stable transfectants thus produced were named according to the constructs used for co-
transfection (R1R3, A1A3 or Vector Control:  VC).  Presence of these constructs in the cells was 
verified using PCR of genomic DNA (Figure 2.2A).  PCR conditions used were the following: 
initial denaturation at 95ºC for 3 min; 30 cycles of 95ºC for 1min, 58ºC for 1 min, 72ºC for 2 min 
followed by a final extension at 72ºC for 7 min.  Sequences of the primers used for the PCR 




using TRIzol (Invitrogen), cleaned with DNaseI (Ambion Inc., Austin TX) and cDNA synthesized 
(iScriptTM, BioRad, Hercules CA).  Expression of recombinant genes was verified by PCR from 
the cDNA and subsequent restriction digestion using HpyCH4V (New England Biolabs, Beverly, 
MA) (Figure 2.2B and 2.2C).  










DEFT_Fwd TCCTCACTGCCATGCTTCT AF526271.1 29-47 
Genomic 
DNA 
  AF355799 92-110 cDNA 
DEFT_Rev TTATAACAAACGGCAAATTCCT AF526271.1 897-918 
Genomic 
DNA 
  AF355799 285-306 cDNA 
 
2.2.3 Acid extraction and affinity purification of retrocyclin peptides 
 
HL60 cells (control, VC, R1R3 and A1A3) were extracted with 5% acetic acid by vortexing for 20 
min, centrifuged for 10 min at 10,000 x g, supernatants were then vacuum-dried and resuspended 
in 0.01% acetic acid.  HL60 acid extracts (equivalent of 20 x 106 cells) were affinity purified using 
anti-RC-101 polyclonal antisera immobilized to a Carbolink™ coupling gel (Pierce Biotechnology 
Inc. Rockford, IL) prepared according to the manufacturer’s instructions.  Immunopurified 
samples were desalted using Sep-Pak C-18 cartridges (Waters, Milford, MA).  The eluates were 
then dried and resuspended in 100  l of 0.01% acetic acid.  100  g of synthetic RC-101 peptide 
was also affinity purified as positive control (RC-101 IP). 
 
2.2.4 Luciferase-based infection assay to determine anti-HIV-1 activity  
 




p24gag) in the presence of vehicle (0.01% acetic acid) or HL60 extracts (from 0.25 x 106 control or 
A1A3 or R1R3 cells) or affinity purified extracts (from 0.625 x 106 control HL60 or VC or R1R3 
or A1A3 cells or RC-101 IP diluted 1:32 times) or RC-101 (20  g/ml) (positive control) for 24 hr.  
Treatments were then removed and the infection was quantified by measuring luciferase using 
Bright-Glo reagents (Promega, Madison, WI) in an LMax luminometer (Molecular Devices, 
Sunnyvale, CA).  Cytotoxicity and metabolic activity of cells were verified by a tetrazolium- based 
MTT assay (R& D systems, Minneapolis, MN) performed on identically treated cells. 
 
2.2.5 Antiviral Infection Assay in suspension cells and HIV-1 p24gag ELISA 
 
Acid extracts of stably transfected HL60 cells were vacuum-dried and resuspended in PBS.  PM1 
cells (105 cells) or PBMCs (106 cells) were treated with PBS (vehicle) or HL60 extracts (from 104 
cells for PM1 and 105 for PBMCs) of control cells or A1A3 cells or 10  g/ml of synthetic RC-101 
and infected with HIV-1 BaL (2 ng of p24/ml) in 100  l of RPMI medium with 20% FBS (R20) 
for 2 hr.  Cells were then washed with 2 ml of R20, resuspended in fresh medium containing the 
treatments and cultured for 5-9 days.  Subsequently on alternate days culture supernatants were 
collected and fresh medium with the corresponding treatments was added.  Viability of the cells 
was measured using trypan blue exclusion assay.  Amount of HIV-1 virus in the culture 
supernatants was quantified by ELISA for HIV-1 p24gag (Perkin Elmer, Waltham, MA). 
 
2.2.6 Immuno-dotblot assay 
 
Peptides RC-100, RC-100b, RC-101, RC-101_2K, synthetic protegrin-1 (PG-1), Rhesus theta 
defensin–1 (RTD-1) and human neutrophil peptides 1-3 (HNP 1-3) or unknown samples were 




with methanol and presoaked in TBS.  The membrane was then probed with 1:1000 rabbit anti-
RC-101 antibody and developed using Immun™- star HRP reagent (BioRad) [162]. 
 
2.2.7 Immunostaining of stably transfected HL60 cells using anti-RC-101 antibody 
 
HL60 cells (VC, R1R3 and A1A3) were fixed on slides (100,000 cells/ slide), immersed in 10% 
Formalin in PBS for 10 min, washed (PBS for 2 min), incubated in Target retrieval solution (Dako 
North America Inc. Carpinteria, CA) for 20 min at 95 C, cooled to 25ºC, washed, blocked (2% 
Goat Serum, 0.1% Triton-X, 0.05% Tween-20, antibody buffer (10 mg/ml BSA/1 mg/ml 
gelatin/PBS) for 20 min and incubated in rabbit pre-immune serum or rabbit anti-RC-101 antibody 
(1:5000 in antibody buffer) overnight.  Slides were washed, incubated in biotinylated goat anti-
rabbit IgG antibody (1:20,000 in 1% goat serum/PBS for 30 min), followed by additional washing 
and treatment with Fluorescein-Avidin D (Vector Laboratories Inc.; 1:500 in PBS for 30 min).  
Cover slips were mounted using Vectashield fluorescence mounting medium and visualized using 
a Zeiss Axiovert 200M microscope system.  
 
Tissues for immunofluorescence staining were fixed in 4% paraformaldehyde and slides were 
prepared by Mass Histology (Worcester, MA).  The slides were deparaffinized, washed with TBS, 
and stained with anti-retrocyclin or pre-immune serum and immunostained the same way as cells.  
The slides were then visualized on a Zeiss Axiovert 200M microscope system with 450 ms 
exposure time for all slides. 
 
2.2.8 Separation of proteins from stably transfected HL60 extracts using reverse-phase 
HPLC 
 




RP- HPLC using the Alliance HT Waters 2795 Separations Module on a C18 Column equilibrated 
in solvent A (aqueous 0.1% TFA).  Elution was done with a gradient of 0- 95 % solvent B (0.08% 
TFA in acetonitrile), for 75 min, at 1 ml/min.  Collected fractions (1 ml each) were vacuum-dried 
and reconstituted in 100  l of 0.01% acetic acid.  Synthetic RC-101 peptide (control) was 
recovered from the fractions eluting at 26-28 min.  A1A3 HPLC fractions (#23-28) were 
electrophoresed on a 16% Tricine-SDS gel and electroblotted on a 0.22  m PVDF membrane at 
180mA for 22 min. The western blot membrane was then processed as described [162] and 
developed with ChemiGlow reagent (Alpha Innotech, San Leandro, CA).  A1A3 RP-HPLC 
fractions (27-30 min) were pooled and the concentration was determined to be (2.13 ng/ l) by 
densitometry measurements using Quantity one 1-D analysis (BioRad).  A luciferase-based assay 
was used to verify the activity of A1A3 HPLC fractions (diluted 3 times in D10) against HIV-1 
BaL (2 ng p24/ml).  
 
MatTek cervicovaginal tissues treated with PBS (control) or 10 g/ml tobramycin were extracted 
with T-PER® reagent (Pierce Biotechnology Inc. Rockford, IL) and separated by RP-HPLC.  20 
g of synthetic retrocyclin (RC-100) was also separated as a positive control.  Synthetic RC-100 
was eluted in fractions collected at 27-29 min. Tissue samples eluted at 27-29 min were vacuum-
dried to near dryness and resuspended in 100 l of 0.01% acetic acid.  HPLC fractions (27-29 min) 
of MatTek tissue extracts (control or tobramycin-treated) and synthetic RC-100 were analysed by 
immuno-dotblot analysis.   
 
2.2.9 Mass Spectrometric analysis 
 




C protease for 30 min before analyzing by mass spectrometry.  In brief, 20 mM Tris [2-
carboxyethyl] phosphine (TCEP) was used to reduce (30 min at 25 °C) the samples, alkylated by 
incubating the samples with iodoacetamide (60 mM; 45 min at 25 °C; pH 8-9) followed by 
digestion with Lys-C (Wako Chemicals, Richmond, VA; 30 min at 37 °C) and subjected to 
MALDI-TOF-MS analysis using a model 4700 Proteomics Analyzer (Applied Biosystems, Foster 
City, CA) as described previously [132].  Lys-C digested RC-101 was desalted using C18 ZipTip 
(Millipore Corp., Billerica, MA) and subjected to Edman degradation on cLC-Procise sequencer 
(Applied Biosystems). 
 
2.2.10 Aminoglycoside mediated read-through of termination codon 
 
Wildtype and mutant retrocyclin cDNAs were subcloned into phCMV-luc-FSR vector to create 
unrescued RC-101 and rescued RC-101 C-terminal luciferase fusion constructs, and verified by 
sequencing.  HOS-CD4-CCR5 cells were cultured in antibiotic free growth medium (D10-) and co-
transfected with 0.5  g of unrescued or rescued (positive control) RC-101 plasmids along with 0.1 
 g of phRL-CMV vector (transfection control containing renilla luciferase gene) using Effectene 
transfection reagent (Qiagen, Valencia, CA).  The next day cells were treated for 24 hr with the 
appropriate aminoglycoside (40  g/ml amikacin or 5 g/ml gentamicin or 10  g/ml tobramycin) or 
D10- for control cells.  Read-through was determined by measuring luciferase and renilla levels 
using a dual luciferase assay (Promega).   
 
TZM-bl cells  (4000 cells/well; 96 well plate) were cultured in D10- and treated with vehicle (PBS 




aminoglycosides as before for 30 min followed by infection with HIV-1 BaL (p24 of 2 ng/ml) at 
37 C for 24 hr.  Subsequently, viral infection was quantified by measuring luciferase levels using 
Bright-Glo reagents (Promega).  Cellular metabolism was monitored by measuring reduction the 
ability of cellular dehydrogenases to reduce MTT to formazan (R& D systems).   
 
TZM-bl cells were cultured on coverslips and treated with PBS control or 10 g/ml of tobramycin 
for 24 hr. The coverslips were then processed for immunofluorescence staining with anti-
retrocyclin (rabbit anti-RC-101 antibody) or pre-immune serum as described above.  
 
For antibody-mediated neutralization experiments, TZM-bl cells (4000 cells/well; 96 well plate) 
were cultured in D10- medium and treated with vehicle (PBS) or 10 g/ml of tobramycin for 24 hr.  
The next day, cells were treated with either rabbit preimmune or anti-retrocyclin serum diluted 
1:10 in D10- medium containing tobramycin or RC-100 (2.5 g/ml).  Two hours later the cells 
were infected with HIV-1 BaL (p24 of 5 ng/ml) at 37 C for 24 hr.  Viral infection was quantified 
as described above.  An MTT assay was performed to confirm that the treatments were not 
cytotoxic (data not shown).   
 
2.2.11 Application of aminoglycosides to organotypic cervicovaginal tissue model  
 
Cervicovaginal tissues were treated topically with 100 l of PBS (control; n = 4) or with 10 g/ml 
of tobramycin (n = 8) for 24 hr.  Viability was assessed on control and tobramycin-treated tissue (n 
=1) using MTT assay kit (MatTek Corp., Ashland, MA).  Cytotoxicity was measured by 




treatment with PBS or tobramycin by using CytoTox96 non-radioactive cytotoxicity assay kit  
(Promega Corp., Madison, WI).  
 
2.3 Results and Discussion 
2.3.1 Creation of promyelocytic cells stably transfected with retrocyclin constructs 
 
-Defensins are formed by posttranslational modification of two 12-residue gene products, each of 
which is processed to give a nonapeptide that contains three cysteines.  The N-terminus of one 
nonapeptide forms a peptide bond with the C-terminus of another nonapeptide, resulting in a cyclic 
18 residue peptide with three intramolecular disulfide bonds [134,136].  To determine if human 
cells have retained the ability to process -defensins, we transfected promyelocytic HL60 cells 
with retrocyclin constructs each encoding a nonapeptide in which the premature termination codon 
was replaced with a glutamine ( 17Q).   
 
Four types of constructs were produced:  R1, R3, A1 and A3 (Figure 2.1).  Aside from the 
corrected premature termination codon ( 17Q), all constructs were engineered to contain two 
termination codons at the end of the gene to ensure read-fidelity.  Constructs with an “R” 
designation terminate after the retrocyclin portion of the gene, while constructs with an “A” 
designation contain the retrocyclin portion with additional downstream residues that might be 
critical for translation and/or processing [134,174].  Constructs with a “1” designation do not have 
any additional residues mutated, while constructs with a “3” designation have the additional Arg to 







Figure 2.1: Design of retrocyclin constructs.  (A) Shows a schematic of the 4 constructs (R1, R3, A1 and 
A3) used for stable transfections along with native retrocyclin cDNA.  All constructs have two termination codons at 
the end to ensure read-fidelity (red).  Constructs A1 and A3 contain additional downstream residues (orange) while 
constructs R1 and R3 lack them.  The two arrows indicate the position at which the two site-directed mutagenesis 
( 17Q and R70K) were performed.  (B) Shows the three possible mature retrocyclin peptides that could be formed 
from the constructs, homodimers of R1 or A1 encoding RC-100 (wild type retrocyclin), heterodimers of A1 and A3 or 





  HL60 cells were co-transfected by electroporation with either R1 and R3, or A1 and A3, and 
propagated in the presence of G418 (300  g/ml) to create stably transfected cell lines.  Stable 
transfection was verified by analyzing genomic DNA and mRNA (Figure 2.2).  Since two 
different constructs were co-transfected for each condition, combinatorially it would be possible to 
generate three different retrocyclin peptides as illustrated in Figure 2.1B.  For example, if cells 
were co-transfected with the R1 and R3 constructs, they could theoretically generate a heterodimer 
(R1R3) or homodimers (R1R1 or R3R3). 
 
 
Figure 2.2: Verification of stable transfection of retrocyclin constructs.  Analysis of the genomic 
DNA and RNA of transfected HL60 cells confirms the stable transfection and transcription of rescued retrocyclin 
constructs respectively.  (A) PCR on genomic DNA template from transfected HL60 cells shows a 215 bp fragment 
representing retrocyclin cDNA construct and a 890 bp fragment of native retrocyclin gene in the genomic DNA of 
A1A3 clones but not in the Vector control (VC) cells.  (B, C) Correction of the premature termination codon of 
retrocyclin cDNA introduces an additional HpyCH4V restriction site the middle of a 87 bp cDNA fragment.  RNA 
isolated from HL60 cells (control, R1R3 clones 1 & 2 and A1A3 clones 1 & 2) was used to make cDNA.  Retrocyclin 
constructs were amplified by PCR using the cDNA as template and digested using HpyCH4V restriction enzyme.  
Electrophoresis of the digested PCR products shows the expected 87 bp fragment in control cells (B) and the expected 





2.3.2 Extracts of promyelocytic cells stably transfected with retrocyclin constructs are active 
against HIV-1 
 
We next analyzed if correcting the termination codon in the retrocyclin constructs could restore the 
translation of biologically active retrocyclin peptides.  The infection of TZM-bl cells with HIV-1 
BaL was significantly reduced when cells were treated with cellular acid extracts of R1R3 cells (P 
< 0.004) and A1A3 cells (P < 0.002) (Figure 2.3A).  A standard tetrazolium MTT assay revealed 
that the extracts did not affect cellular metabolism at the concentrations used in the experiment 
(Figure 2.3E).  Addition of A1A3 cell extracts to HIV-1 infected PM1 cells (Figure 2.3B) and 
PBMCs (Figure 2.3C) showed significant (P < 0.002 and P < 0.004 respectively) decrease in the 
viral titer as compared to cells treated with control HL60 cell extract.  A trypan blue exclusion 
assay was performed in PBMCs to monitor cell viability (Figure 2.3F).  We next affinity purified 
R1R3 and A1A3 cell extracts using anti-RC-101 antibody and confirmed the antiviral activity in a 
luciferase-based assay system (Figure 2.3D).  Interestingly, A1A3 cell extracts were found to be 
consistently more active than equivalent amounts of R1R3 cell extract, which suggests a role for 
the downstream residues in retrocyclin processing.  These results indicate that biologically active 
recombinant retrocyclin peptides can be synthesized in human promyelocytic cells.  As a next step 






Figure 2.3: Extracts from HL60 cells stably transfected with retrocyclin constructs are active 
against HIV-1 infection.  (A) TZM-bl cells were treated with extracts or peptide as indicated in the figure and 
infected with HIV-1 BaL (6.5 ng/ml p24) for 24 hr.  Infection was measured as percent luciferase activity compared to 
cells treated with control cell extract (Average RLU of control HL60 extract = 178,200).  (B, C) PM1 cells and 
PBMCs were treated with extracts or peptide as indicated and infected with HIV-1 BaL (2 ng/ml p24) and cultured for 
5-9 days.  Bars represent percent BaL HIV-1 levels in the supernatants collected on days 5 (B) and 9 (C).  The amount 
of p24 in PM1 cells treated with control extract = 76.85 ng/ml and in PBMCs treated with control extracts = 55.99 
ng/ml.  (D) TZM-bl cells were treated with immunopurified (IP) extracts or peptides as indicated and infected with 
BaL HIV-1 (p24 = 2 ng/ml) for 24 hr.  Infection was quantified as percent luciferase activity compared to cells treated 
with control HL60 cell IP extracts (Average RLU = 764,460).  Error bars represent SEM.  n = 3-4, # P < 0.004, * P < 
0.002, ** P <0.0005.   (E)  Cellular viability of TZM-bl cells treated with HL60 acid extracts as indicated was 
determined by measuring the reduction of MTT after 24h (n = 3). Bars represent percent viability as compared to 
vehicle control and error bars represent SEM.  (F) Cell death was monitored in PBMCs treated with the acid extracts 




2.3.3 Immunofluorescence staining of stably transfected HL60 cells reveals retrocyclin 
peptides 
 
Immuno-dotblot analyses revealed that our anti-RC-101 antibody specifically recognized lysine-
containing human retrocyclin analogs (synthetic RC-101 and RC-101_2K) and RC-100 (i.e. wild 
type form) to a lesser extent (Figure 2.4A) but not human neutrophil peptides 1-3, or peptides with 
very similar tertiary structure including rhesus theta defensin-1 (RTD-1) and protegrin-1 (PG-1) 
(Figure 2.4B).  This antibody was used to visualize the expressed retrocyclin peptides in the stably 
transfected HL60 cells by immunofluorescence staining, which revealed that R1R3 cells and A1A3 
cells were brightly stained as compared to Vector Control (VC) cells (Figure 2.4C).  Slides treated 
with pre-immune serum showed no staining (data not shown).  Note that the staining of A1A3 was 
brighter than R1R3 and the morphology of A1A3 cells was smaller than VC cells.  Experiments 
were next designed to purify and confirm the identity of the expressed retrocyclin peptides from 






Figure 2.4: Immunofluorescence staining of stably transfected HL60 cells reveals retrocyclin 
peptides.  (A) Retrocyclin peptides RC-100, RC-101 and RC-101_2K peptides (in duplicates) and (B) RC-100, RC-
100b, RC-101, protegrin-1 (PG-1), rhesus theta defensin –1 (RTD-1), and human neutrophil peptides 1-3 (HNP 1-3) 
were dotted (0-8 ng / 4  l dot) on a PVDF membrane and subjected to immuno-dotblot analysis.  (C) Vector control, 




followed by biotinylated goat anti-rabbit IgG secondary antibody and then stained using FITC-avidin.  Slides were 
visualized using Zeiss Axiovert 200M microscope system at 40 X magnification.  The three rows show FITC staining, 
DIC and the merged image respectively.  Scale bar represents 20  m. 
 
2.3.4 Stably transfected promyelocytic cells produce retrocyclin peptides 
 
Reverse-phase HPLC (RP-HPLC) was utilized to purify the recombinant retrocyclin peptides from 
stably transfected HL60 cell extracts.  Figure 2.5A shows the RP-HPLC trace of A1A3 and 
synthetic RC-101.  Synthetic RC-101 was recovered in fractions collected at 26-28 min.  A1A3 
HPLC Fractions collected from 23-30 minutes were analyzed on a 16% Tricine-SDS-gel.  Control 
samples did not contain any protein bands at the expected size while fractions from R1R3 cell 
extracts revealed protein bands of about 6 kDa size (data not shown).   Interestingly, A1A3 HPLC 
fractions revealed multiple protein bands, which we further analyzed by western blot (Figure 
2.5B).  The western blot analysis revealed bands at sizes corresponding to a monomer, dimer and 
trimer of retrocyclin.  Interestingly, the presence of multimeric forms of retrocyclin has been 
independently observed by Daly and colleagues [175].  Furthermore, the RP-HPLC purified A1A3 
fractions inhibited entry of HIV-1 BaL in TZM-bl cells (Figure 2.5C).  The IC50 of retrocyclin 







Figure 2.5: Stably transfected promyelocytic cells produce retrocyclin.  (A) Shows the RP-HPLC 
trace of A1A3 cell extract (from 108 cells) and 50  g of synthetic RC-101.  (B) Western blot of A1A3 HPLC fractions 
(23-28 min) using rabbit anti-RC-101 antibody.  The arrows indicate the multimeric forms of retrocyclin observed in 
A1A3 fractions.  (C) TZM-bl cells were infected with HIV-1 (p24 = 2 ng/ml) in the presence or absence of pooled 
A1A3 fractions (final dilution 1:6 in D10) or 2  g/ml of RC-101 for 24 hr.  Infection was quantified by luciferase 
measurement (Average RLU of Vehicle control with virus = 85,450).  Error bar represents SEM and n = 3-6, * P < 
0.0015 ** P <0.0001.  MALDI-TOF MS spectra of Lys-C digested (D) synthetic RC-101_2K, (E) synthetic RC-101 
and (F) A1A3 HPLC fraction 26 reveal that A1A3 cells produce RC-101.  
 
To determine the identity of the retrocyclin peptide expressed by A1A3 cells, HPLC fraction 26 
was analyzed by mass spectrometric analysis (MALDI-TOF-MS) at the Microchemical and 
Proteomics Facility, Emory University.  Analysis of A1A3 Fraction 26 revealed peaks with masses 
1889.775 Da (oxidized) and 1895.890 Da (reduced), which is nearly identical to the expected mass 




agreement with reduction of the three disulfide bridges in the molecule.  Furthermore, treatment 
with iodoacetamide yielded mass species of 2238.081 Da for the A1A3 fraction 26 and 2238.071 
Da for RC-101 corresponding to the predicted 6-fold-alkylated form of RC-101 (expected mass = 
2238.097 Da).  Comparison of spectrum of the Lys-C digest of reduced/alkylated synthetic RC-
101_2K (peak at 1123.577 Da; peptide cleaved at two Lys-Gly bonds; Figure 2.5D), synthetic RC-
101 (peak at 2256.097 Da; peptide cleaved at a single Lys-Gly bond; N-terminal sequence 
determined as: Gly-Ile-Cys-Arg-; Figure 2.5E) and A1A3 fraction 26 (peak at 2256.010 Da) 
suggests that the A1A3 cells are expressing RC-101 (Figure 2.5F).  These data confirmed that 
correctly folded mature retrocyclin peptides can be expressed by human cells.  In the following 
experiments we explored alternative methods to express the peptide endogenously.  Of particular 
interest was the effect of aminoglycosides in mediating varying degrees of termination codon read-
through as previously described [151,153-155,163-165].  
 
2.3.5 Aminoglycosides mediate read-through of termination codon of retrocyclin gene and 
restore anti-HIV-1 activity 
 
We tested the ability of three commonly used aminoglycosides (gentamicin, amikacin, and 
tobramycin) to induce termination codon read-through of retrocyclin cDNA.  The native 
retrocyclin gene was fused with a luciferase reporter at the C-terminus to create 2 constructs:  
unrescued RC-101 and rescued RC-101 (positive control) as shown in Figure 2.6A.  These 
constructs were transfected into HOS-CD4-CCR5 cells, grown in the presence of varying 
concentrations of aminoglycosides, and the degree of read-through quantified by measuring 
luciferase.  Application of tobramycin (10  g/ml) was the most effective, producing a 26-fold 




Having thus established the optimal aminoglycoside concentration required to achieve read-
through of retrocylin cDNA, we next determined if aminoglycosides could restore the translation 
and anti-HIV-1 activity of native retrocyclin peptides.  HeLa-derived cells lines such as TZM-bl 
cells can natively express retrocyclin mRNA (data not shown).  We applied aminoglycosides to 
TZM-bl cells and challenged them with HIV-1 BaL.  We found that cells treated with gentamicin 
and tobramycin significantly (P < 0.0005 and P < 0.0001 respectively) inhibited HIV-1 infection 
as compared to untreated cells (Figure 2.6C).  The effect was modest when compared to inhibition 
by synthetic peptides.  Cell viability, determined by a tetrazolium based MTT assay, was not 
affected by the application of aminoglycosides at the mentioned concentrations (Figure 2.6E).   
 
 
Figure 2.6: Aminoglycosides mediate read-through of the premature termination codon 




of the luciferase fusion constructs unrescued RC-101 and rescued RC-101 along with native retrocyclin cDNA.  (B) 
HOS-CD4-CCR5 cells cultured in antibiotic free medium (D10-) were transfected with unrescued RC-101 (negative 
control) or rescued RC-101 (positive control) plasmids along with phRL-CMV vector (transfection control).  The next 
day transfected cells were treated with PBS for control cells or aminoglycosides at the indicated concentrations and 
allowed to grow for 24 hr.  Read-through was determined by measuring luciferase levels.  Data is expressed as fold 
increase in luciferase expression normalized to renilla levels.  (C) TZM-bl cells grown in D10- were treated for 30 min 
with PBS, RC-101 (2.5  g/ml), RC-100 (2.5  g/ml) or aminoglycosides as shown in the figure and infected with HIV-
1 BaL (2 ng/ml p24) for 24 hr followed by luciferase measurement.  Error bars represent SEM.  n = 3-6, # P < 0.007 * 
P < 0.0005 ** P <0.0001.  (D) TZM-bl cells cultured on cover slips were treated with PBS (Con) or 10 g/ml 
tobramycin (Tob) and then immunostained with rabbit pre-immune or anti-retrocyclin serum using a biotinylated 
secondary antibody FITC-avidin system.  (E) Cellular cytotoxicity was assessed by performing an MTT assay on 
TZM-bl cells treated with indicated amount of peptide or aminoglycosides (n = 3).  Bars represent percent metabolic 
inhibition as compared to control (vehicle + virus). (F) TZM-bl cells, treated with either PBS, tobramycin (10 g/ml) 
or RC-100 (2.5 g/ml), were incubated with preimmune serum or anti-retrocyclin serum as indicated and infected with 
HIV-1 (p24 of 5 ng/ml).  Data is represented as percent infection. Error bars represent SEM.  n = 3, + P < 0.018 
Statistical significance was determined by two-tailed Student t-test. 
 
In order to visualize the retrocyclins expressed by application of aminoglycosides, we performed 
immunostaining.  TZM-bl cells were treated with PBS control or 10 g/ml  tobramycin and stained 
with anti-retrocyclin antibody or pre-immune serum.  Control cells showed no staining while cells 
treated with tobramycin revealed brightly stained cells suggesting that aminoglycosides can induce 
the expression of retrocyclin peptides (Figure 2.6D).   
 
We next incubated TZM-bl cells with tobramycin (10 g/ml) for 24 hr, and then treated the cells 




that cells treated with preimmune serum showed a modest yet significant reduction in infection as 
compared to cells treated with anti-retrocyclin antibodies (P < 0.018), suggesting that the antibody 
inhibited the endogenous retrocyclins.  These data confirm that the anti-HIV-1 activity observed is 
due to the endogenous retrocyclin peptides expressed when tobramycin was applied to cells.   
 
2.3.6 Aminoglycosides induce production of retrocyclin peptides in cervicovaginal tissues 
 
We next analyzed the ability of aminoglycosides to induce the expression of retrocyclin peptides in 
an organotypic model cervicovaginal tissue.  Tissues were treated apically with tobramycin or 
control (PBS) for 24 hr and anti-retrocyclin immunohistochemical analysis was performed.  
Interestingly, tissues treated with tobramycin alone and stained with anti-retrocyclin antibody 
revealed brightly stained cells (Figure 2.7A) suggesting that production of retrocyclin peptides is 
induced upon application of aminoglycosides.  Lactate Dehydrogenase (LDH) activity in the 
medium underlying the tissues was performed to determine tissue cytotoxicity.  The LDH assay 
revealed that application of 10 g/ml tobramycin was not cytotoxic to the tissues (Figure 2.7B).  
In addition, treatment of tobramycin did not affect the metabolic activity adversely, which was 
determined by an MTT assay performed on one tissue (data not shown).   
 
In order to purify endogenous retrocyclins expressed in the tissues, we utilized reverse- phase 
HPLC.  Figure 2.7C shows an HPLC trace of control, tobramycin-treated tissue extracts as 
compared to synthetic RC-100 peptide.  Synthetic RC-100 peptide was recovered in fractions 
collected at 27-29.  Corresponding fractions from control and tobramycin-treated tissues were 




retrocyclin peptides were recovered in fractions 27-29 min in tobramycin-treated tissue samples 
but not in control tissue samples.  The amount of retrocyclin (RC-100) expressed in tobramycin-
treated cervicovaginal tissues was estimated by densitometry to be approximately 1.6 g/tissue.  
Together these studies show that aminoglycosides are promising molecules to suppress the 
premature termination codon of retrocyclin transcripts and restore the ability of cervicovaginal 
tissues to protect cells from HIV-1.  
 
 
Figure 2.7: Expression of retrocyclins in cervicovaginal tissue model using aminoglycosides.  
(A) Cervicovaginal tissues were treated with PBS (Con) or 10 l tobramycin (Tob) and incubated with rabbit pre-




secondary antibody and then stained using FITC-avidin.  B) Cytotoxicity was determined by measuring Lactate 
dehydrogenase (LDH) activity in media underlying the tissues treated with PBS or tobramycin as indicated.  Bars 
represent absorbance measured as 490 nm and error bars represent SEM; n = 6.  (C)  HPLC trace of extracts of tissues 
treated with 10 g/ml tobramycin (Tissue + Tob) and 20 g of synthetic RC-100.  (D) RC-100 synthetic peptide 
(indicated amounts), HPLC fractions 27-29 of control, tobramycin-treated and RC-100 were dotted on a PVDF 
membrane and analyzed by immuno-dotblot. 
 
2.4 Conclusion 
Identifying effective drugs to prevent HIV-1 infection and other viral infections is essential for 
countering the spread of these diseases.  Exogenous (synthetic) retrocyclins exhibit full activity in 
the complex environment of vaginal fluid and the peptide is very well tolerated in organotypic 
human cervicovaginal tissue models [162].  Moreover, HIV-1 evolves little resistance during 
continued passaging in the presence of the peptide [147].  For these and other reasons, retrocyclins 
have emerged as potential topical microbicides to protect against sexually- transmitted HIV-1 
infections.   
 
In this study we have taken a different path towards developing -defensin therapeutics.  The 
human pseudogenes that encode the demidefensin precursors whose post-translational processing 
gives rise to mature retrocyclin are expressed at the mRNA level in multiple organs, including the 
spleen, bone marrow, thymus, testis and skeletal muscle [134]  and cervicovaginal epithelia 
(A.M.C., unpublished data).  By transfecting human myeloid cells with plasmids containing 
retrocyclin genes without a premature termination codon, we demonstrated that the “machinery” 
needed to process, trim, splice and oxidize retrocyclin precursors was available in human myeloid 




terminates at the end of the retrocyclin gene and a longer form that contains (A1A3) additional 3’ 
untranslated residues (UTR).   Interestingly, A1A3 cells expressed higher levels of retrocyclin 
peptides as compared to R1R3 cells indicating a role for additional residues in the translational 
efficiency of these peptides.  This was not altogether surprising as other studies have shown that 
the length of the 3’-UTR regulates translation efficiency [174,176].  Finally, we showed that 
aminoglycoside-treated cells and cervicovaginal tissues could produce retrocyclins endogenously 
by suppressing the premature termination codon in their endogenous mRNA transcript. 
 
Since approximately 30% of inherited disorders may result from premature termination codon 
mutations, there has been tremendous interest and some progress in developing and applying 
agents that can read-through premature UAA, UAG or UGA termination codons [155].  Although 
aminoglycosides, as used in this study, have been most widely investigated, exciting new agents 
such as PTC-124, have also appeared [177,178].  In a sense, human retrocyclin-deficiency is also 
an inherited disorder, albeit one with an incidence of 100%.  It is caused by a premature 
termination codon mutation that occurred after human lineage diverged from the lineage we share 
with orangutans, lesser apes and old world monkeys.  Since HIV-1 and other viruses that currently 
infect humans have evolved in the absence of selective pressure exerted by retrocyclins, the ability 
to reawaken this ancestral molecule could be used to strengthen the innate immune system’s ability 




CHAPTER THREE: CATIONIC POLYPEPTIDES ARE REQUIRED FOR 
ANTI-HIV-1 ACTIVITY OF HUMAN VAGINAL FLUID 
 
3.1 Introduction 
Approximately 40 million people have been infected with HIV-1 worldwide according to the 2004 
World Health Organization estimates [179].  There has been a dramatic increase in the global 
spread of human immunodeficiency virus type 1 (HIV-1) especially via the heterosexual mode of 
transmission [179,180]. At present, nearly 60% of infected individuals are women [181,182].  The 
natural sexual transmission of HIV occurs through mucosal surfaces such as vaginal or rectal 
mucosa [183].  Vaginal and rectal subepithelial stromal tissues are densely populated with dendritic 
cells (DC), macrophages and T-cells that express both CD4 and the HIV-1 co-receptors, CXCR4 and 
CCR5 [4,184].  Mechanisms whereby HIV-1 journeys across the mucosal epithelia are not 
completely understood, but may directly involve the epithelial cells [185].  Once the virus reaches 
the lamina propria, it can either directly infect macrophages or T lymphocytes or adhere to (or infect) 
dendritic cells, whose traffic to the regional lymph nodes converts them into sites of vigorous viral 
replication [186,187].  Whereas considerable attention in immunopathogenetic research on HIV-1 
has been focused on acquired immunity, only recently has the role of innate immunity surfaced.   
 
A layer of mucosal fluid covers the vaginal epithelium, and is composed of secretions from the 
cervical vestibular glands, plasma transudate, endometrial and oviductal fluids [188,189].  The 
fluid covering the vaginal mucosa protects against entry of pathogens into deeper tissues, including 
periodic sloughing of mucus and underlying cells to remove adherent microbes.  The vagina is a 
host for numerous commensal microorganisms, which release organic acids and antimicrobial 




neutrophils contribute antimicrobial peptides to the milieu of the vaginal fluid, including 
lysozyme, lactoferrin, secretory leukocyte protease inhibitor (SLPI), human neutrophil peptides 
(HNP-1, -2 and -3) and human -defensins (HBDs) [111].  We hypothesized that the sum total of 
these and likely other antimicrobial peptides and proteins contribute to the innate host defense of 
the vagina.   
 
To date, evidence for the role of antimicrobial polypeptides in vaginal anti-HIV-1 host defense has 
been largely circumstantial.  Lysozyme and lactoferrin have been shown to inhibit the infection by 
HIV-1 in vitro by preventing the adsorption and penetration of the virus [113,191-193].  Human -
defensins have been shown to inhibit HIV-1 replication [131] through modulation of the CXCR4 
coreceptor as well by interacting directly with the virions.  Several reports have shown that the 
level of SLPI is reduced in vaginal fluid of HIV infected persons [117,194].  SLPI has been shown 
to block HIV-1 infection in monocytes and T-cells by preventing the internalization of the virus 
prior to reverse transcription [115,117].  However, the action of SLPI is still debatable since other 
reports suggest that SLPI by itself has no effect on HIV-1 replication [118].  HNP-1-3 inhibit HIV-
1 replication in vitro by two mechanisms:  in the absence of serum they inhibit HIV-1 replication 
prior to integration of the virus in CD4+ T cells and in the presence of serum they interfere with 
the signaling pathways on target cells and block the nuclear import and transcription of HIV-1 
genome [128,129,195].  
 
In the current report, we explored the biological role of cationic antimicrobial polypeptides in 
protecting the vaginal mucosa from infection by HIV-1.  We revealed that the cationic proteins in 




cervicovaginal tissues.  We utilized a proteomic approach to identify 18 different cationic 
polypeptides in vaginal fluid, most of which have been previously reported to exhibit antimicrobial 
properties.  While individual polypeptides at physiological concentration did not exhibit antiviral 
activity against HIV-1 infection, a combination of the peptides partially restored the antiviral 
activity.  Selective depletion of cationic polypeptides from whole vaginal fluid reduced the 
intrinsic anti-HIV-1 activity.  Most importantly, anti-HIV-1 activity of depleted fluid was restored 
upon repletion with the cationic polypeptide extract.  Collectively, these studies suggest that the 
intrinsic anti-HIV-1 activity of vaginal fluid is an aggregate effect of all its active cationic 
polypeptide components.    
 
3.2 Materials and methods 
3.2.1 Reagents 
 
Human neutrophil lysozyme and human milk lactoferrin were purchased from Sigma-Aldrich, (St. 
Louis, MO).  Recombinant calgranulin A (S100A8) and calgranulin B (S100A9) were purchased 
from Abnova Corp. (Taipei, Taiwan).  Recombinant Cystatin B and SLPI were purchased from 
R&D Systems (Minneapolis, MN).  Histone H2A was purchased from Upstate USA Inc. 
(Charlottesville, VA).  Cathepsin G was purchased from Bachem Bioscience Inc. (King of Prussia, 
=>?@$$A,B*79:"!"1$%-defensins, HBD-1 and -2, were generous gifts from Dr. Tomas Ganz (David 
C,<<,"$DB)**/$*<$E,#:B:",F$GHI>F$H>?@$$5),$&-defensins, HNP-1, -2 and -3, were purified from 
human leukocytes and were generous gifts from Dr. Ganz and Dr. Robert I. Lehrer (David Geffen 






3.2.2 Collection and processing of vaginal fluid 
 
Vaginal fluid was collected from post-menarcheal but pre-menopausal healthy female donors after 
informed consent as per the guidelines of the Institutional Review Board of University of Central 
Florida.  Donors with current or recent vaginal infections and those under antibiotic treatment for 
any reason were excluded from the study using a questionnaire.  To collect undiluted vaginal fluid, 
an Instead SoftCup (Ultrafem, Inc., La Jolla, CA) was inserted into the vagina as per the 
manufacturer’s instructions, and removed after 30 min.  The SoftCup was then centrifuged for 10 
min at 1000 × g in a 50 ml sterile conical tube to collect the fluid sample [196].  Retrieved samples 
were then homogenized by sonication on ice using a microtip ultrasound probe (ten 2-3 sec 
pulses).  These “minimally manipulated” whole vaginal fluid samples stored in aliquots at -20 C.  
This method enabled us to collect approximately 200 l to 1 ml of vaginal fluid per collection.  For 
most antiviral cell culture assays, the vaginal fluid was not manipulated further.  For antiviral cell 
culture assays the vaginal fluids were extracted with 5% acetic acid for 2 hrs with gentle agitation, 
and the clarified supernatant was vacuum-dried and resuspended to the original volume in 100 mM 
sodium phosphate pH 7.4.  To prepare the samples for two-dimensional proteomic analyses, the 
undiluted vaginal fluids were extracted using 5% acetic acid, vacuum dried, and resuspended in 
0.1% hexadecyl trimethyl ammonium bromide (CETAB)/10% acetic acid/ 3× acid urea loading 
dye (9M urea, 5% acetic acid and methyl green).   
 
3.2.3 Selective depletion of cationic polypeptides from vaginal fluid  
 
Carboxymethyl weak cation-exchange resin (CM resin; Bio-Rad, Hercules, CA) was used to 




vaginal fluid buffer (VFB) (60 mM NaCl and 20 mM KH2PO4; pH 6), which has been reported to 
be similar in electrolyte composition to vaginal fluid [111].  The CM resin was washed with VFB 
and centrifuged at 10,000  g for 10 min and the overlying VFB was removed.  Equal volumes of 
vaginal fluid from 10-23 donors was pooled, added to an equal bed volume of CM resin pre-
equilibrated with VFB, and incubated overnight at 4 C with gentle agitation.  The CM resin was 
sedimented by centrifugation (16,000 × g, 5 min) and the cationic polypeptide-depleted 
supernatant was collected (hereunto termed “CM-depleted vaginal fluid”).  The cationic 
polypeptides bound to the CM resin were extracted in subsequent 2 hr and 24 hr extractions using 
5 resin volumes of 5% acetic acid at 4 C.  The extracts were, pooled, vacuum-dried and 
resuspended to the original volume of vaginal fluid.  
 
3.2.4 Cell lines and viruses 
 
PM1, TZM-bl and H9 cells were obtained from the NIH AIDS Research and Reference Reagent 
Program.  TZM-bl cells are a HeLa-derived cell line that stably expresses CD4 and CCR5 and 
contains the luciferase gene under the control of the HIV-1 promoter [170].  TZM-bl cells were 
grown in high glucose Dulbecco Modified Eagle Medium (DMEM) (Mediatech, Herndon, VA) 
supplemented with 100 U/ml penicillin, 100 g/ml of streptomycin and 10% FBS.  Passages 5-15 
were used for experiments, and no change in cell behavior was observed between passages.  PM1 
cells were maintained at a density of 0.4- 0.8  106 /ml in RPMI1640 supplemented with 100 U/ml 
penicillin, 100 g/ml streptomycin, 100 mM HEPES and 20% FBS (Gemini Bio-Products, 
Woodland, CA).  H9 cells were cultured in the same manner as PM1 cells except 10% FBS was 




Research and Reference Reagent Program.  HIV-1 BaL was propagated in PM1 cells over 16 days.  
Supernatants containing virus were collected every other day starting 5 days post-infection, passed 
through a 0.45  m filter, and stored in aliquots at -80°C.  HIV-1 IIIB was propagated similarly 
using H9 cells.  Virus was quantitated by a sensitive commercial ELISA for p24gag (PerkinElmer, 
Boston, MA).   
 
3.2.5 Assays to determine anti-HIV-1 activity of vaginal fluid and cationic polypeptides  
 
TZM-bl cells were seeded in 96-well dishes (4000 cells/well). After 24 hours, cells were treated in 
triplicate with 50 l culture medium containing whole vaginal fluid, CM-depleted vaginal fluid, 
peptides recovered from CM resin, vehicle control (100 mM sodium phosphate pH 7.4), individual 
recombinant or purified peptides at physiological concentration (Table II), or combinations 
thereof.  Culture media, or virus diluted in culture media (2 ng/ml p24 for BaL and 5 ng/ml p24 for 
IIIB), in 50 l was immediately added to each well, and allowed to incubate at 37 °C/ 5% CO2 for 
24 hrs.  Subsequently, luciferase activity was measured with Bright-Glo reagents (Promega, 
Madison, WI) according to manufacturer’s instructions using an LMax luminometer (Molecular 
Devices, Sunnyvale, CA).  Cytotoxicity and the metabolic activity of the cells were verified by a 
tetrazolium-based (MTT) assay as per the manufacturer’s instructions (R&D Systems, 
Minneapolis, MN).   
 
3.2.6 Two-dimensional gel electrophoresis of vaginal fluid 
 
Acid-extracted vaginal fluid samples were electrophoresed on a 12.5% native acid urea- 
polyacrylamide gel (AU-PAGE) in the first dimension at 75V for 16-18 hr [197,198].  The gel was 




acid) to visualize the protein bands.  The entire lane of the first dimension AU-gel was excised, 
washed twice for 5 min each in dH2O followed by two 5 min washes with 50 mM Tris pH 8.8, and 
soaked for 10 min in equilibration buffer (50 mM Tris, 6M Urea, 2% SDS, 20% glycerol, and 
bromophenol blue ad libitum, pH 8.8) containing 10 mg/ml DTT.  The gel strips were 
electrophoresed in a 16% Tricine–SDS-PAGE as the second dimension for 20 hr at 40 mA [199].  
Protein spots were visualized by SYPRO Ruby gel stain (Bio-Rad), excised, and stored at 4°C in 
1% acetic acid until analyzed by mass spectrometry.  
 
3.2.7 Identification of cationic polypeptides of vaginal fluid 
 
The proteins were then subjected to trypsin digestion and mass spectrometric analysis (MALDI-
TOF-MS/MS analysis [200] at the Microchemical and Proteomics facility at Emory University, 
GA as described earlier [201,202].  GPS Explorer 2.0 software (Applied Biosystems, Foster City, 
CA) and a MASCOT (http://www.matrixscience.com/) search engine were used for identification 
of peptide fragments.  The NCBI non-redundant database and the Mammalia taxonomy were used 
for the searches. 
 
3.2.8 Human Cervicovaginal Tissue Model 
 
Organotypic “EpiVaginal” cultures of normal human vaginal-ectocervical epithelial cells and 
immuno-competent dendritic cells were propagated as suggested by MatTek Corporation 
(Ashland, MA).  Each 60 mm2 tissue adhered tightly atop a microporous membrane insert, and was 
maintained at the air-liquid interface using 5 ml of maintenance medium (MatTek).  Tissues (3 per 




vaginal fluid diluted 1:1 with PBS for 30 min and then rinsed twice with warm PBS.  Tissues were 
then topically applied with either 100  l of PBS (control), PBS containing 25 ng p24 of HIV-1 
BaL, or PBS containing BaL and vaginal fluid (equivalent to 50% of whole fluid), for 24 hr.  
Treatments were then removed and tissues were washed with 100  l warm PBS, then vaginal fluid 
(50%) or PBS vehicle were re-applied in 50  l.  A one-time dose of 1×106 HIV-1 BaL-infected 
PM1 promyelocytic cells were included underneath the microporous insert to sustain the initial 
HIV-1 infection, and were removed after 2 days.  Basal maintenance media was changed every 
other day, and the topical (apical) treatments were removed and re-applied on days 3 and 6 post-
infection.  On day 9 post-infection, DNA was extracted from 2 tissues per treatment condition 
using Qiagen’s DNA Micro kit.  Total protein was extracted from the third tissue per treatment 
condition and assayed by ELISA for HIV-1 p24gag (PerkinElmer).    
 
3.2.9 Detection of HIV-1 provirus in human cervicovaginal tissue 
 
HIV-1 infection of cervicovaginal tissues was assessed by real-time PCR quantitation of the HIV-1 
BaL env 6,",$J.,/!1:-,$1*$%-actin controls) in total tissue DNA isolated 9 days post-infection. HIV-
1 BaL primers used were: 5’- AACACCTCAGTCATTACAC -3’ and 5’- 
TACATTGCTCTTCCTACTTC -KLF$ +):B)$ !7M/:<8$ !$ NOO$ 9M$ .,6:*"$ *<$ P!I$ 6MQRO@$ $ %-actin 
primers used were:  5’- CCTTCCAGCAGATGTG -3’ and 5’- GGTGTAACGCA ACTAAG -3’, 
+):B)$!7M/:<8$!$QOS$9M$ .,6:*"$*<$);7!"$%-actin.  200 ng DNA was mixed with 2× Sybr Green 
supermix (Bio-Rad), 200 nM each primer, and dH2T@$$5.:M/:B!1,$RO$U/$.,!B1:*"0$+,.,$B!..:,#$*;1$
using the MyiQ real-time PCR detection system (Bio-Rad), and HIV-1 BaL levels were 




analysis and gel electrophoresis revealed that single PCR products were amplified for each gene.  
Moreover, the env PCR product was verified by sub-cloning into pCR4-TOPO (Invitrogen), 





Luciferase assays were performed in triplicate for each treatment condition in each experiment, 
with relative light units in vehicle-only control wells set as 100% infection.  Each treatment 
condition was analyzed by one-way ANOVA followed by Tukey pairwise comparison.  Mass 
spectrometric analysis for each polypeptide identified was performed in duplicate, and protein 
spots with a confidence index (C.I %) greater than 85 percentile, combined with ion scores of 40 
for one or more peptides matched to each protein, were considered positively identified [200].  
 
3.3 Results  
3.3.1 Human vaginal fluid is intrinsically active against HIV-1. 
 
The mucosal layer lining the vaginal epithelial cells is rich in antimicrobial polypeptides that 
provide a crucial barrier against invading microbial and viral pathogens [111,190].  Although some 
of these polypeptides have been shown to exhibit antiviral properties [115,129,160,193,203,204], 
detailed analysis of the intrinsic anti-HIV-1 activity of vaginal fluid has not been reported.  Herein, 
we explored the activity of the cationic polypeptide components of vaginal fluid against HIV-1.  
TZM-bl cells were treated with either PBS (vehicle control) or vaginal fluid diluted in DMEM 




(HIV-1 IIIB; Figure 3.1B) strains of HIV-1.  After 24 hours, excess virus was removed and 
infection was quantitated as a measure of luciferase expression.  As compared to vehicle-only 
controls, vaginal fluid extracts significantly reduced the infection of both viral strains in a dose 
dependant manner.  As measured by a standard MTT tetrazolium assay, the vaginal fluid extracts 
were not cytotoxic (data not shown).  These results indicate that human vaginal fluid intrinsically 
inhibits the entry of HIV-1 into host cells. 
 
Figure 3.1: Human Vaginal fluid intrinsically inhibits HIV-1 infection.  TZM-bl cells were treated 
with PBS (vehicle control) or vaginal fluid diluted in DMEM high glucose medium to a final concentration as 
indicated in the figure and were subsequently infected with (A) HIV-1 BaL (2 ng/ml p24) or (B) HIV-1 IIIB (5 ng/ml 
p24) for 24 hr. Infection was measured as a percent reduction in luciferase activity as compared to infected vehicle-
only control (relative light units = RLU). Experiments were performed using 4 different pools of vaginal fluid each in 
triplicate. As compared with control, double asterisks indicates P <0.0002; a single asterisk indicates P <0.0005. Error 






3.3.2 Anti-HIV-1 activity resides in the cationic fraction of vaginal fluid. 
 
Experiments were designed to selectively remove the cationic polypeptides from whole vaginal 
fluid to determine if this depletion reduced the anti-HIV-1 activity of the fluid.  Whole, undiluted 
vaginal fluid was collected from healthy donors using an Instead SoftCup.  A weak cation 
exchange resin, CM-Prep (Bio-Rad), was utilized to deplete the cationic peptides and proteins 
from vaginal fluid, whilst sparing the concentrations of remaining proteins and electrolytes.  We 
pioneered this technique, and have characterized the selective depletion of cationic polypeptides 
from nasal fluid [197].  The activity of whole vaginal fluid extract, CM-depleted vaginal fluid, and 
the polypeptides extracted from the CM resin were tested individually against HIV-1 BaL (Figure 
3.2A) and HIV-1 IIIB (Figure 3.2B) in TZM-bl cells for 24 hours.  Cells treated with whole 
vaginal fluid showed significant reduction in infection as compared with PBS control (P <0.0002; 
n = 13), while the CM-depleted fluid did not inhibit infection.  Similar to whole vaginal fluid, 
polypeptides extracted from the CM resin exhibited significant anti-HIV-1 activity as compared 
with both the PBS control and CM-depleted vaginal fluid (P < 0.0002; n = 14).  Taken together, 
these data indicate that the anti-HIV-1 activity of vaginal fluid is contained in the cationic fraction.  
Whole vaginal fluid, CM-depleted vaginal fluid, and the extracted cationic polypeptides were used 





Figure 3.2: Depletion of cationic proteins from vaginal fluid increases HIV-1 infection.  TZM-
bl cells were treated with vehicle control, whole vaginal fluid extract (Whole-VF), CM-depleted vaginal fluid (CM-
depl-VF) or the recovered peptides from the CM-resin (CM-extract) and infected for 24 hrs with HIV-1 (A) BaL p24 = 
2ng/ml (B) IIIB p24= 5ng/ml. Luciferase levels were measured and percent infection was calculated as in Figure 1. 
The results are from experiments performed with 4 different pools of vaginal fluid, each repeated thrice. Asterisk 
indicates P <0.0002. 
 
3.3.3 Identification of cationic polypeptides of vaginal fluid. 
 
We next utilized a novel proteomic technique to identify cationic polypeptide components in 
vaginal fluid.  The cationic polypeptide fraction from whole, undiluted vaginal fluid was subjected 
to AU-PAGE (the first dimension of a two-dimensional gel), which separates polypeptides based 
on cationic charge density [198,205],  A slice from the AU-PAGE was inserted into a Tricine-
SDS-PAGE gel (the second dimension) to separate low molecular weight polypeptides by size 69.  
Gels were stained with SYPRO Ruby (Figure 3.3) or silver (not shown).  Spots representing single 




spectrometry (MALDI-TOF/TOF).  Each polypeptide spot was sequenced from samples excised 
from both silver stained and SYPRO Ruby stained gels.   
 
 
Figure 3.3: Identification of cationic polypeptides in vaginal fluid.  W)*/,$-!6:"!/$</;:#$JQO$U/?$+!0$
subjected to first dimensional electrophoresis in an AU-PAGE followed by Tricine SDS PAGE as the second 
dimension. The SYPRO Ruby stained two-dimensional gel of whole vaginal fluid extract showing the protein spots 
identified by MALDI-TOF mass spectrometric analysis. Each polypeptide spot and their reported role in host defense 
are listed in Table I. Unlabeled arrows were identified as fragments of human albumin. 
 
Table 3.1 lists the corresponding protein spots labeled in Figure 3.3 and indicates how each spot 




polypeptide.  Spots with a confidence index (C.I.%) greater than 85% were considered positive.  
Note that several smaller fragments of albumin were also detected, which are indicated by 
unlabelled arrows.  We also discovered two novel, unnamed polypeptide fragments (Figure 3.3, 
spot #5 and 19) in vaginal fluid.  In total, we have positively identified 18 unique cationic 
polypeptides in vaginal fluid, of which many have reported roles in host defense against HIV-1 
infection [113,115,129,131,206,207]. 
 
3.3.4 Comparison of proteomic profiles of whole and CM-depleted vaginal fluids reveals 
cationic polypeptides that contribute to anti-HIV-1 activity.  
 
Two-dimensional gel electrophoresis was next used to characterize the cationic polypeptides that 
remained in the vaginal fluid after CM depletion, as well as those that were extracted with the CM 
resin. Figure 3.4 compares 2-D gel electrophoretograms of whole vaginal fluid, CM-depleted 
vaginal fluid, and the polypeptides extracted from the resin. Among the polypeptides that were 
absent in CM-depleted fluid yet recovered from the resin include lysozyme, cystatin B, calgranulin 
B, histone H2A, HNP1-3, lipocalin-2 and cathepsin G (indicated by arrows in Figure 3.4A and 
3.4C). Some components are reportedly active against HIV-1 (lysozyme and HNP1-3), while the 
anti-HIV-1 activities of the others have not been reported. We next explored which of the cationic 






Figure 3.4: Comparison of proteomics profiles of whole vaginal fluid and Depleted vaginal 
fluid.  Two-#:7,"0:*"!/$6,/$,/,B1.*M)*.,0:0$*<$QO$U/$*<$J>?$+)*/,$-!6:"!/$</;:#F$JP?$HE-depleted vaginal fluid and 
(C) the extract of bound proteins from CM-resin was performed. The arrows in panels A and C indicate protein spots 
that were recovered in the polypeptide extract, and are listed in Table 3.4. The circles in panel B indicate the region 




Table 3.1: Cationic polypeptides identified in vaginal fluid by two-dimensional analysis and 
MALDI-TOF MS/MS analysis. 
 
 Spot ID Accession # MW (Da) Scoreb C.I.%c Role in Host Defense 
1 Albumin gi|23241675 45130.4 90 100 
 Transport of metabolites, drugs and 
toxins, Transcytosis of  




gi|4261868 20534.5 51 100 
 Bacteriostatic, Sequesters Iron 
siderophores  [209,210].  
3 Chain A, Cathepsin-G gi|20664220 26740.9 227 100 
 Serine protease, Chemoattractant, 






gi|7767000 19976.3 41 100 
 Antibacterial, sequesters Iron 
siderophores[209,210].  
5 Unnamed protein product  gi|14041892 23795.5 44 100  (Unknown). 
6 Histone H2B gi|184086 11324.1 55 99  Antibacterial [213-216] . 
7 H2A histone family gi|4504251 14086.9 113 100  Antibacterial [213-216].  
8 
Fatty acid binding protein 5 
E-FABP 
gi|4557581 15154.5 196 100 
 Intracellular fatty acid trafficking, 
Stabilization of leukotrienes, Skin 
inflammation[217,218].  
9 Human Galectin-7 gi|3891470 14934.8 71 100 
 S-lectin involved in cell-adhesion 
[219,220], migration  immune 
response [221,222].  
10 Lysozyme  gi|3660304 14599.2 100 100 
 Antibacterial and antiviral 
[191,197,223,224].  
11 Lysozyme (dimer) gi|14278473 14693.1 90 100 
 Artifact obtained after extraction 
from CM-resin [197].  
12 Cystatin B-Human gi|68783 11166.6 54 98 
 Cysteine proteinase inhibitor, 
immunomodulator, activates NO 
synthesis in macrophages [225,226]. 
13 Calgranulin B  gi|7417329 13102.5 88 89  Antibacterial [227,228] 
14 Histone H2A family member gi|10800144 13927.8 126 100  Antibacterial [213-216]  
15 Histone H4 gi|223582 11230.3 127 100  Antibacterial [213-216]  
16d H2A histone family member gi|18105045 13897.8 118 81  Antibacterial [213-216]  
17 Cystatin A gi|4885165 10999.7 120 100 
 Cysteine proteinase inhibitor, 
immunomodulator [226,228]  
18 Calgranulin A gi|29888 10930.8 197 100  Antibacterial [227,229] 
19 Unnamed protein product  gi|14041892 23795.5 58 100  (Unknown) 
20 
Human Neutrophil peptide 3 
HNP1-3 
gi|229858 3489.6 63 99  Antimicrobial, [128,129,230-232]  
 
a   The numbers correspond to the labeled spots in Figure 3.3   
b   Ion Score of one or more peptide fragments that match a protein in the database 
c   Confidence Index percentage 






3.3.5 Individual cationic peptides and proteins at physiologic concentrations are not active 
against HIV-1.   
 
We tested the anti-HIV-1 activity of 13 cationic polypeptides that were either purified from natural 
sources or recombinant proteins.  Table 3.2 lists the physiologic concentration of cationic 
polypeptides in vaginal fluid from healthy donors as identified in this study and in Valore et al. 
[111].  Each polypeptide was tested for anti-HIV-1 activity at its measured physiological 
concentration.  TZM-bl cells were treated with individual polypeptides at the final concentrations 
given in Table 3.2, infected with HIV-1 BaL or HIV-1 IIIB, and at 24 hrs anti-HIV-1 activity was 
measured by quantifying luciferase expression.  At physiological concentrations, none of the 
polypeptides alone inhibited viral entry (data not shown).  These data suggest that the antiretroviral 
activity of vaginal fluid may be a result of two or more cationic antimicrobial polypeptides acting 
in synergy.     
Table 3.2:   Physiological concentration of cationic proteins that contribute to anti-HIV-1 
activity of vaginal fluid. 
 
Protein Concentration ( g/ml) Method of detection Reference 
Calprotectinab 34 7 Semiquantitative Western blot and densitometry [111,227,229]  
Cystatin Ba 32.16 Densitometry This study 
Lysozymea 13 2 Semiquantitative Western blot and densitometry [111,223]  
Histone H2Aa 11.04 Densitometry This study 
Cathepsin Ga 10.88 Densitometry This study 
Lactoferrin 0.9 0.2 Semiquantitative Western blot and densitometry [111,113,193]  
SLPI 0.7 0.1 Semiquantitative Western blot and densitometry [111,115,117]  
HBD-2 0.57 0.13 Semiquantitative Western blot and densitometry [111,131]  
HNP-1-3ac 0.35 0.07 Semiquantitative Western blot and densitometry [111,128,206,233]  
HBD-1 0.04 0.02 ELISA [111,131]  
 
a    Represents the arrows indicated in Figure 3.4A  and 3.4C 
b    Calprotectin, heterodimer of calgranulin A and calgranulin B was tested as individual peptides  







3.3.6 Cationic polypeptides of vaginal fluid synergize to inhibit HIV-1 infection. 
 
The abundance of antimicrobial peptides in vaginal fluid with often overlapping roles in host 
defense suggests that the anti-HIV-1 activity is not a result of actions from individual peptides.  
Moreover, our studies also indicate that the individual polypeptides at physiological concentration 
do not prevent entry of HIV-1 into host cells.  We therefore hypothesized that these polypeptides 
must act in concert to prevent the HIV-1 infection.  To test our hypothesis, we prepared a cocktail 
of 13 available recombinant or natural peptides at physiological concentrations as shown in Table 
3.2.  TZM-bl cells were treated with either the polypeptide mix either alone or the polypeptide mix 
added to CM-depleted vaginal fluid, and were subsequently infected with HIV-1 (Figure 3.5).  
While the polypeptide mix alone reduced infectivity approximately 40%, this was not significant 
as compared with vehicle-only control.  Moreover, the addition of the polypeptide mix to CM-
depleted fluid was also not completely restorative.  Due to availability, not every polypeptide 
identified was represented in the cocktail, which may have contributed to the incomplete 
restoration of CM-depleted fluid.  This hypothesis is supported in our next experiment.  
 
Interestingly, the cationic polypeptide extract (cleaved from the CM resin) was completely 
restorative to CM-depleted fluid (P = 0.00012; n = 14), and the combined anti-HIV-1 activity was 
equivalent to the activity of whole vaginal fluid (Figure 3.5).  These data suggest that the anti-
HIV-1 activity of vaginal fluid is primarily contained in the cationic fraction, and that the activity 






Figure 3.5: Cationic polypeptides of vaginal fluid synergize to inhibit HIV-1 infection. TZM-bl 
cells were treated as indicated in the figure and infected with BaL (p24 = 2ng/ml) for 24 hr. Luciferase was then 
measured as described earlier and percent infection was calculated. Asterisk indicates P < 0.00015. Experiments were 







3.3.7 Vaginal fluid protects against HIV-1 infection of human cervicovaginal tissue. 
 
We next tested whether vaginal fluid could protect organotypic human cervicovaginal tissues 
against HIV-1 infection.  This ex vivo model closely resembles the native mucosae of the 
ectocervix and vagina, containing full-thickness epithelia composed of vaginal-ectocervical cells 
that are interspersed with immuno-competent dendritic (Langerhans) cells in the basal and 
suprabasal layers.  To study the role of vaginal fluid in reducing HIV-1 infection and integration of 
the proviral DNA into the host genome, cervicovaginal tissues infected with HIV-1 BaL in the 
absence or presence of an apical film of vaginal fluid were compared.  The tissues were treated 
with PBS (vehicle control) or vaginal fluid diluted 1:1 in PBS for 30 min prior to infection with 
HIV-1 BaL (p24 = 25 ng/tissue) diluted in PBS (control) or in 50% vaginal fluid.  24 hrs post 
infection, excess virus was removed and PBS control or 50% vaginal fluid was reapplied to the 
apical tissue surface.  Total tissue DNA was extracted 9 days post infection and the proviral DNA 
levels were assessed by real-time quantitative PCR of the env gene of HIV-1 BaL.  Compared to 
tissues topically infected with HIV-1 BaL alone, cervicovaginal tissues that were treated with 
vaginal fluid for 30 minutes prior to the addition of HIV-1 BaL had approximately 4-fold fewer 
copies of proviral DNA, although this trend was not statistically significant due to variability in the 
untreated condition (Figure 3.6A).  However, viral titer as quantified by p24gag ELISA was 
significantly lower in cervicovaginal tissues treated with vaginal fluid as compared with control 
tissues (P = 0.0091; n = 2; Figure 3.6B).  These studies imply that vaginal fluid plays an important 






Figure 3.6: Vaginal fluid inhibits HIV-1 infection of human vaginal tissues.  Human vaginal 
organotypic cultures were treated with PBS control or 50% vaginal fluid and infected with HIV-1 BaL. 9 days post 
infection tissues were harvested for DNA or protein analysis. (A) Realtime quantitative PCR of HIV-1 BaL proviral 
DNA corresponding to 700bp region of env gene was performed in BaL versus BaL + vaginal fluid (VF) infected 
tissues. (B) HIV-1 p24 protein levels in BaL versus BaL + VF infected tissues. Asterisk indicates P = 0.0091. Error 
bars represent SEM. 
 
3.4 Discussion 
The mechanisms by which the vaginal mucosa protects against sexually transmitted and other 
pathogenic infections are not completely understood.  While several studies have focused on the 
adaptive immune system of mucosal surfaces of the female reproductive tract, scant attention has 
been focused on the innate immune factors in vaginal secretions [234-237].  Evidence is 




invading pathogens [111,238,239].  On the contrary, this surface and its overlying fluid are replete 
with antimicrobial polypeptides that act as effectors of innate host defense.   
The current study provides evidence that cationic polypeptides contribute significantly to the 
intrinsic biological activity of vaginal fluid against HIV-1 infection.  Proteomic analysis of the 
cationic polypeptide fraction of vaginal fluid revealed numerous cationic antimicrobial and host 
defense polypeptides.  Polypeptides with known microbicidal effects that have been identified in 
our study and previously identified in mucosal secretions include lysozyme, lactoferrin, 
cathelicidin [240,241]F$%-#,<,"0:"0F$&-defensins and SLPI [111,238].  Although each of the above 
polypeptides reportedly prevented HIV-1 infection, their activities were realized only when 
assayed at supraphysiologic concentrations.  In the current study we determined that, at 
physiological concentration, none of the cationic polypeptides tested individually was active 
against HIV-1.  However, a cocktail of the peptides added back to CM-depleted vaginal fluid 
partially restored the activity.  Partial (rather than complete) restoration of activity may be 
reflective of the following:  1) some of the recombinant proteins may not exhibit the same anti-
HIV-1 activity as that of the purified or natural proteins in the secretions, 2) while we created the 
cocktail with individual polypeptides, the full activity of certain proteins (e.g. calgranulins A and 
B) may be best realized in their heterodimeric form, and 3) due to availability, several polypeptides 
that we identified could not be included in the polypeptide cocktail.  Any or all of these conditions 
support the premise that the collective cationic polypeptide fraction is responsible for anti-HIV-1 
activity of vaginal fluid.  Indeed, when the extracted cationic polypeptide fraction (bound to the 
CM-resin) was used to reconstitute the CM-depleted fluid, anti-HIV-1 activity was restored 
completely.  Anti-HIV-1 activity of vaginal fluid is likely due to the collective cationic 





Whole vaginal fluid was collected from healthy donors using a diaphragm-like device (Instead 
SoftCup), which enabled the collection of whole undiluted cervicovaginal fluid [196].  In contrast, 
other commonly used methods of cervicovaginal fluid collection, such as extraction from 
preweighed tampons or vaginal lavage [111,242,243], can suffer from protein adhesion to the 
tampon or a dilute lavage of unknown protein concentration.  Unlike lavage, the Instead SoftCup is 
convenient and can be self-inserted, thus women are more receptive to donating cervicovaginal 
fluid.  While no one method of collection is perfect, approaches that enable the retrieval of whole, 
undiluted fluid may afford the best representation of the condition in vivo.   
 
Lactic and other organic acids that result in the low pH of human vaginal fluid (normally pH 3.8-
4.5), as well as volatile compounds such as H2O2, are thought to contribute to microbial host 
defense [112,190].  Our studies were designed to minimize or eliminate the effects of these factors, 
as the acidity of the vaginal fluid was neutralized (pH 7.4) prior to subjecting the fluid to anti-HIV-
1 assays.  Moreover, although the all of the anti-HIV-1 activity was contained in the collective 
polypeptide extract, the procedures required for extraction would inactivate or remove H2O2 and 
other volatile compounds.  Both whole vaginal fluid and the collective cationic polypeptide 
fraction were equally active against HIV-1, and thus the activity against HIV-1 was purportedly 
not a result of ancillary components of the cervicovaginal fluid.   
 
Histones and their fragments were some of the more abundant polypeptides identified in vaginal 
fluid.  Valore and colleagues identified histone H2B in the vaginal fluid of a healthy donor using a 




identified histone fragments in every vaginal fluid sample tested.  Histones have been shown to 
possess antibacterial properties and are released from activated neutrophils [213,214].  Why are 
histones present in mucosal secretions – do these proteins confer an active function, or are they just 
byproducts of cellular decay?  Until recently, the latter was the most plausible explanation.  
However, a current study by Brinkmann and colleagues provided an alternative mechanism behind 
the presence of extracellular histones [214].  They reported that activated neutrophils release NETs 
(neutrophil extracellular traps), long elaborations of chromatin and neutrophil elastase that are 
independent of apoptosis or necrosis.  NETs bound and inactivated both gram-positive and gram-
negative bacteria, and prevented their dispersal.  Moreover, NETs were abundant in experimental 
dysentery and in spontaneous human appendicitis.  It is not known whether inflammatory cells in 
the cervicovaginal mucosa elaborate NETs and their associated histones as a host defense 
mechanism, or if histones are released simply as a result of cellular damage. 
 
T1),.$ 01;#:,0$ *<$ -!6:"!/$ </;:#$ 1)!1$ 0M,B:<:B!//8$ 0,!.B),#$ <*.$ 1),$ M.,0,"B,$ *<$ %-defensins using 
sensitive antibodies were able to immunodetect low levels in vaginal fluid [244].  However, we did 
not uncover these peptides in our proteomic search, likely due to the scant concentration of these 
peptides and thus the low chance that they would be identified as a major spot on two-dimensional 
=>C3@$ $ W):/,$ %-defensins have been shown to inhibit HIV-1 infection (50% inhibition at 20 
g/ml concentration) in human oral epithelial cells [131], the concentrations in vivo are 35- to 500-
fold lower (Table 3.2) suggesting that they may not play a major role in antiretroviral host 
defense.  Moreover, our studies revealed that HBD-1 and HBD-2 alone failed to inhibit HIV-1 





Surprisingly, vaginal fluid contains components that are permissive to the transmission of HIV-1.  
For example, samples of cervicovaginal lavage fluid that contained higher concentrations of 
calgranulin A have been shown to exhibit greater activation of HIV-1 in latently infected 
monocytic cells [245].  The human neutrophil-derived serine protease cathepsin G has also been 
shown to increase the susceptibility of macrophages to HIV-1 infection in vitro [211].  While the 
mechanism is not known, insights into the role of mucosal polypeptides that increase the 
probability of transmission and infection of HIV-1 would be critical in the development of 
effective antiretroviral treatments and preventatives.  Taken together the above studies reveal that 





CHAPTER FOUR: ANALYSIS OF PUTATIVE CLUSTERS OF 
REGULATORY MODULES IN THE RETROCYCLIN PROMOTER 
 
4.1 Introduction 
The expression of many antimicrobial peptides, such as defensins, can be induced in response to 
pathogenic assaults.  Defensins, produced by both leukocytes and epithelial cells, are classified 
into 3 sub-families ( -, - and -defensins) based on their intramolecular disulfide bonds and 
tertiary structure.  Some -defensins, such as human neutrophil peptides 1-3 (HNP 1-3), are 
constitutively expressed and stored in the granules of myeloid cells, while beta-defensins, such as 
human beta-defensin -1 (HBD-1), are constitutively expressed by keratinocytes [246-248].  On the 
other hand, certain -defensins such as HBD 2-4 are inducible by cytokines like interleukin-1 (IL-
1), tumour necrosis factor (TNF), or lipopolysaccharide (LPS) [246,249,250].   
 
The third subfamily of defensins known as -defensins, exist as pseudogenes in humans due to the 
presence of a premature termination codon which prevents translation of the protein.  However, -
defensin mRNA has been detected in the human bone marrow, spleen, thymus, testis, skeletal 
muscle and cervicovaginal epithelial cells [134].  In our recent study we revealed that functional 
anti-retroviral human theta-defensins (retrocyclins) can be expressed in promyelocytic cells and 
cervicovaginal tissues [150].  Further, we showed that aminoglycosides allow read–through of the 
premature termination codon, thereby enabling the successful translation of native retrocyclin 
transcripts [150].  Having established that functional retrocyclins can be produced by human cells, 





In silico analysis of the upstream region of the retrocyclin gene (DEFT-1) revealed numerous 
transcription factor binding elements that are putatively regulated by IFN such as Interferon 
Regulatory Factors (IRF-1/IRF-2), Interferon Stimulated Gene Factor-3 (ISGF-3), Interferon 
Consensus Sequence Binding Protein (ICSBP) and others.  Our preliminary studies indicated that 
retrocyclin mRNA expression was upregulated in epithelial cells in response to interferon type-I 
treatment or HIV-1 infection.  Further, we have demonstrated that phosphorylated signal 
transducers and activators of transcription (STAT-1/-3) complex binds to the ISGF-3 recognition 
site on the DEFT-1 promoter resulting in upregulation of retrocyclin gene transcription (A.L.C., 
unpublished studies).  Many of the IFN-inducible genes are regulated in a positive and negative 
manner by cis-acting elements like IRF-1 and IRF-2 respectively [251-253].  Reports by various 
groups have suggested that ICSBP/IRF-8 acts as a repressor for IRF-1 induced genes and IFN-beta 
regulated genes [251,254-256].  Some models speculate that ICSBP mediates its repressive effect 
by interfering with the binding of the ISGF-3 activator complex [257].  In this chapter we reveal 
that ICSBP may have a role in negative regulation of retrocyclin gene expression. 
 
An independent genome-wide in silico study (K.S., unpublished data) based on the presence of 
‘clusters of regulatory modules’ (CRM) revealed the recurring presence of a immune response 
cluster in the human chromosome 8p23 region.  This cluster was defined by the presence of IRF-
1/IRF-2, ISGF-3, AP-1 and NF- B sites within a 250 bp region.  Such a cluster was found at 
about 1.5kb upstream of the retrocyclin genes.  We have examined the activity of these putative 
regulatory clusters by cloning them into enhancer trap reporter vectors and examining reporter 




4.2 Materials and Methods 
4.2.1 Maintenance of cell lines 
 
HeLa cells were obtained from ATCC and cultured using DMEM with 10% FBS, 100  g/ml of 
penicillin and 100 U/ml of streptomycin.  HL60 cells were procured from ATCC and were 
cultured in Iscoves’s DMEM with 20% FBS, 100 U/ml penicillin and 100  g/ml streptomycin 
(I20). 
 
4.2.2 Prediction of retrocyclin promoter region 
 
Genome contigs of the human 8p23 region were downloaded from NCBI database.  Theta-defensin 
genes (DEFT) were identified by BLAST analysis.  A 3kb region upstream of the transcription 
start site was extracted for further analysis.  Putative transcription factor binding sites were 
predicted using TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess) 
 
4.2.3 Construction of plasmids 
 
Human genomic DNA was isolated from HL60 cells using DNeasy kit (Qiagen, Valencia, CA) as 
per the manufacturer’s instruction.  Promoter fragments were PCR amplified as indicated in 
Figure 4.2.  PCR products were electrophoresed on an agarose gel using 1X TBE buffer and 
verified for size.  PCR fragments were then restriction digested with enzymes KpnI (New England 
Biolabs, Beverly, MA) and SacI (New England Biolabs) and ligated into appropriately linearized 
pGL3-promoter vector (New England Biolabs) using T4 DNA ligase.  The ligation reactions were 




selected using 100  g/ml of ampicillin.  Positive clones were verified for sequence integrity at the 
Florida State University sequencing center, Tallahasse, FL or Genewiz Inc. North Brunswick, NJ. 
 
4.2.4 Transfection and luciferase assay 
 
HeLa cells were seeded at a density of 4000 cells /well in a 96-well plate and allowed to grow for 
2 days.  Cells were then transfected with 100  g of positive control (pGL3-control), vector control 
(pGL3-promoter), or promoter constructs using Effectene reagent (Qiagen) as per the 
manufacturer’s instructions.  Cells were stimulated with IFN-beta (1 Unit/ml), or treated with DEX 
(10-5 M) (Sigma-Aldrich, St. Louis, MO), or both as indicated.  Twenty-four hour post-
transfection, cells were lysed and luciferase activity was measured using Bright Glo luciferase 




Data is represented as fold increase over base line.  Raw data was normalized to pGL3-basic 
vector.  The threshold was set to the activity of control vector (pGL3-prom).  Experiments were 
repeated four times. Statistical significance was determined by Wilcoxon-rank sum test.  All 
statistical analyses were performed using the statistical package R (www.r-project.org). 
 
4.3 Results 
4.3.1 Computational analysis of retrocyclin promoter region  
 
The DEFT genes were located on the chromosome 8 by BLAST analysis and the sequence of a 3 




were predicted using Transcription Element Search Software (TESS) in the TRANSFAC database.  
The search revealed the binding sites for transcription factors IRF-1/IRF-2, ISGF-3, ICSBP or 
IRF-8 that are IFN response elements. In addition, we also predicted NF- B and AP-1 binding 
sites that are located on numerous genes involved in immune response [258,259].   Figure 4.1 
shows the transcription factor binding sites located in the 3 kb region upstream of DEFT gene.    
 
Figure 4.1: Schematic representation of the putative cluster on retrocyclin promoter.  Figure 
illustrates the native retrocyclin gene along with a 3 kb upstream region.  The transcription factor binding sites located 
on the putative cluster of regulatory module (CRM) are marked.  The region amplified to create constructs NV-CLS, 
SK-CLS and NS-CLS are shown. 
 
Most of the predicted clusters were present within 1.4-1.7 kilobases upstream of the gene start site.  
This 1.5 kilobase separation was representative of the distance between a distal CRM and the gene 
start site by computational analysis (K.S. personal communication).  From the regions that 
contained the clusters, we amplified and cloned two different overlapping fragments into an 




NV-CLS, a 533 bp region containing the predicted cluster.  Similarly, the computationally 
identified cluster (SK-CLS) was also cloned into the enhancer trap vector as shown in Figure 4.1.  
It is important to note that the SK-CLS cluster is located upstream of a copy of another retrocyclin 
gene in the chromosome 8p23 region and is 81.5% similar to the sequence shown in Figure 4.2. 
 
Figure 4.2: Sequence of an enhancer cluster upstream of retrocyclin gene.  Figure shows the 
sequence of the region -1750 bp to -1150 bp upstream of the retrocyclin gene.  The transcription factor binding sites 
predicted using TESS is highlighted.  The black arrows represent the NV-CLS fragment and the blue arrows indicate 
the SK-CLS and NS-CLS fragments. 
 
4.3.2 IFN response elements contribute to activity of retrocyclin promoter 
 
Our preliminary analysis on the activity of SK-CLS and NV-CLS revealed that SK-CLS fragment 
showed higher expression of luciferase than NV-CLS when transfected into HeLa cells (Figure 
4.3A).  However, this was observed in a cell lineage specific manner, and only certain HeLa cell 




observed differences in expression, we compared the transcription factor binding sites in SK-CLS 
and NV-CLS fragments.  We identified an ICSBP/IRF-8 binding site in NV-CLS, but not in SK-
CLS.  ICSBP/IRF-8 has been shown to be a repressor for IFN-inducible genes [254-256,260].  In 
order to understand the role of ICSBP/IRF-8 in the regulation of this cluster, a deletion construct 
NS-CLS (Figure 4.1) was created using a forward primer located downstream of the ICSBP 
binding site and cloned into pGL3-prom vector (Figure 4.2).   
 
4.3.3 Role of ICSBP/IRF-8 in the regulation of putative clusters of regulatory modules 
located on retrocyclin promoter. 
 
Constructs SK-CLS, NV-CLS and NS-CLS or pGL3-prom (vector control) were transfected into 
HeLa cells and treated with vehicle control (Figure 4.3A), 10-5 M Dexamethasone (DEX), an 
inhibitor of ICSBP/IRF-8 (Figure 4.3B), 1 Unit/ml of IFN-  (Figure 4.3C), or DEX and IFN-  
(Figure 4.3D).  Twenty-four hours post-transfection, cells were lysed and luciferase was 
quantified.   Treatment with DEX in cells transfected with NV-CLS, but not SK-CLS or NS-CLS 
increased the expression of luciferase (1.5 fold) as compared to vector control, suggesting a role 
for ICSBP/IRF-8 in the regulation of retrocyclin gene expression.  Although the application of 1 
Unit/ml of IFN-  to transfected cells showed only a modest increase in the activity of the enhancer 
fragments after 24 hr, addition of DEX to cells primed with IFN-  showed an increase in the 
activity of the NV-CLS fragment.  A Wilcoxon rank sum statistical analysis of the activity of NV-
CLS was determined to have a p-value = 0.05 (Figure 4.3B, 4.3C and 4.3D).  This shows that the 







Figure 4.3: Activity of retrocyclin enhancer clusters.  HeLa cells were transfected with pGL3-prom 
(vector control) or SK-CLS or NV-CLS or NS-CLS and treated with vehicle control or 10-5 M Dexamethasone (DEX) 
or 1 Unit/ml of IFN-  for 24 hr.   Activity of the enhancer clusters was measured by quantifying luciferase.  Data is 
represented as fold increase over baseline (pGL3-basic).  The dotted line represents the activity of the SV40 minimal 
promoter of control vector.   
 
4.4 Discussion 
In this study, we have identified CRM’s that respond to a cohort of transcriptional regulators (IRF-
1/2, ISGF-3, ICSBP, NF- B and AP-1) upstream of the retrocylin genes.  Further, we have 




was thought that the expression of ICSBP was restricted to cells of lymphoid origin, but some 
groups have isolated active ICSBP from epithelial cells [261,262].  In our hands, we found that 
application of dexamethasone, an inhibitor of ICSBP increased the activity of the retrocyclin 
enhancer cluster in cervicovaginal epithelial cells.  Activating the transcription of retrocyclin genes 
using interferons and restoring the translation using aminglycosides might provide the host cell 
with a potential shortcut in the activation of its antiviral defense.   
 
Interestingly, despite being a pseudogene, retrocyclin gene transcription is responsive to HIV-1 
infection and treatment with IFNs in cell lines (A.L.C., unpublished studies).  This raises 
interesting possibilities about the gene itself since it resides in the highly polymorphic 8p23 region 
in the human genome [134,137,263,264].  It is known that genomes give birth to novel genes in 
polymorphic regions that witness high levels of recombination, called the ‘gene nurseries’ [265].  
Given that the 8p23 region is polymorphic and the retrocyclin gene itself is lost only recently in 
evolution (in hominids), it is possible that the region is currently undergoing changes [134].  
Following this line of reason, one can expect the current state of retrocylin genes (expressed 
pseudogenes) to be nothing but a snap shot in evolutionary history, and a single point mutation 
could reverse these dormant genes into active genes.   
 
In conclusion, we have demonstrated that the retrocyclin genes are under the control of a complex, 
tightly regulated cluster with Interferon being an important hub in this regulatory network.  
Knowledge of retrocyclin gene cluster regulation would enable us to exploit their interferon 





CHAPTER FIVE: CONCLUSION 
 
Sexual transmission of HIV-1 continues to be the most common mode of spread of HIV-1 
infection [3,4].  Despite decades of research efforts, there are no effective drugs to treat HIV-1 
infection.  Development of HIV-1 vaccines has been difficult due to the rapid mutation rate of the 
virus.  Therefore, there is an urgent need for effective prophylactic measures active against HIV-1 
to curb the spread of the AIDS pandemic.  Prevention methods such as condom use are effective to 
prevent HIV-1 entry.  However, women who are at greatest risk of acquiring HIV infection often 
are unable to negotiate condom use, which is under the control of the male sexual partner.  Topical 
vaginal microbicides are a viable HIV-1 prevention strategy that provides women with control 
over their sexual health [71,266,267].   
 
In our studies, we have taken a simple approach to translate a human theta-defensin pseudogene, 
retrocyclin and activate an innate antiviral mechanism in human cells.  Theta-defensins are 18-
residue macrocyclic peptides formed by the head-to-tail ligation of two nona-peptides, and are 
potent inhibitors of HIV-1 infection.  Whilst theta-defensin genes (DEFT) are intact in Old World 
monkeys, they exist as pseudogenes in humans [134].  In this work, we revealed that, upon 
correction of the premature termination codon in DEFT pseudogenes, human myeloid cells 
produce cyclic, antiviral retrocyclins peptides indicating that these human cells have retained the 
intact machinery to make cyclic peptides.  Further, we exploited the ability of aminoglycoside 
antibiotics to suppress the premature termination codon in retrocyclin transcripts to produce 
functional peptides active against HIV-1.  Since tobramycin and other aminoglycosides could 




aminoglycoside-based topical vaginal microbicides might be useful in preventing sexual 
transmission of HIV-1 [150].    
 
The primary sites of HIV-1 infection are the vaginal mucosal surfaces that are replete with 
antimicrobial proteins or polypeptides that are effectors of innate host defense [111].  Previous 
studies by other groups have analyzed the role of one or more antimicrobial peptides in host 
defense.  However, the anti-retroviral activity of the antimicrobial peptides present in human 
vaginal fluid at physiological concentrations has not been not clearly understood.  Our study 
indicates that cationic polypeptides contribute to the majority of the intrinsic anti-HIV-1 property 
of vaginal fluid.  We identified 18 different cationic polypeptides using a proteomic approach in 
minimally manipulated vaginal fluid.  When these cationic peptides were tested individually at 
physiological concentration they failed to prevent HIV-1 infection, but a mixture of commercially 
available cationic peptides partially restored the anti-HIV-1 activity.  Moreover, depletion of 
cationic polypeptides from vaginal fluid reduced the anti-HIV-1 activity, while addition of the 
cationic polypeptide extract restored the anti-HIV-1 property.  This suggests that the intrinsic 
property to inhibit HIV-1 entry resides in the cationic polypeptide fraction of human vaginal fluid 
[132].     
 
In spite of the presence of numerous antimicrobial peptides, prevalence and transmission of HIV-1 
continues to rise.  Reduction in the expression of antimicrobial peptides in vaginal fluid may be 
associated with increased risk of HIV-1 infection [111,132].  Therefore, enhancing the expression 
of antiviral peptides such as retrocyclins during these periods could help in preventing HIV-1 




clusters of regulatory modules located in the gene upstream region.  This regulatory cluster 
contained various transcription factor binding sites that are involved in IFN response pathway.  
One of the transcription factor binding sites: Interferon Stimulated Gene Factor -3 (ISGF-3) was 
determined to be associated with activated signal transducers and activators of transcription 
(STAT) complex and upregulate the expression of retrocyclin (A.L.C. unpublished study).  
Another factor called Interferon Consensus Sequence Binding Protein (ICSBP) acted as a negative 
regulator of retrocyclin gene expression.  Our data suggest that despite being a pseudogene, 
retrocyclin expression is regulated in a positive and negative manner.  Understanding the 
regulation of retrocyclins by interferons would help in enhancing the expression of retrocyclins.  A 
combination of interferons and aminoglycosides could help to activate and express endogenous 
retrocyclin peptides to prevent HIV-1 infection.  
 
In conclusion, we have shown that if the premature termination codon in retrocyclin transcript is 
restored human myeloid cells can express cyclic active retrocyclin peptides [150].  Moreover, the 
premature termination codon can be readthrough by aminoglycosides to express endogenous anti-
retroviral retrocyclins [150].  The desirable properties of retrocyclins and its congeners, such as 
broad spectrum activity against various strains of HIV-1 [141-143], activity in the acidic pH of 
human vaginal fluid [162], low cytotoxicity to human cells and ectocervical tissues [150,162] 
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